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INTRODUCTION 
                                            
The most common cause for physical and psychological stresses in post 
pubertal young women are menstrual disorders and infertility.  
 A survey conducted by World Bank in 2013 showed that the fertility 
started dropping 10 years back with 17% decline every year from 2000 
which was reported in a very popular magazine of India. 
  In another famous journal survey, 10% of urban Indian couples in   
reproductive age group are infertile.  
Most females with irregular menses ignore this complaint till they are 
criticized as infertile women. The leading causes for menstrual irregularity are 
Polycystic ovarian syndrome and Hypothyroidism. Polycystic ovarian syndrome is the 
most common endocrine disorder among the reproductive age group women [1, 2, 3, 4] 
and it races with other metabolic disorders resulting in complications if left untreated. 
PCOS is a complex disorder with chronic anovulation, hyperandrogenism and 
hyperinsulinemia with multiple cysts in ovaries [5]. Western population studies show 
the prevalence of PCOS to be about 4-8% among young women [3].  In India studies 
show the prevalence of 5-10% [1]. Even though the definition of PCOS is not fully 
established, they usually present with different complaints from simple acne to 
complicated infertility based on their response to the available androgen. Most of 
them are obese and are at risk of developing Diabetes mellitus,  
dyslipidemia, metabolic syndrome, cardiovascular disorders, carcinoma of 
endometrium or cervix [6,7, 8].  
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Hypothyroidism is another complicated disorder found particularly in young 
reproductive age group women. Hypothyroid patients may present with simple 
weakness and fatigue to complicated infertility. Apparently healthy young females 
selected as controls in studies were found to have hypothyroidism incidentally and 
that too in a higher percentage. This implies that many healthy looking women may 
have subclinical or occult and even overt hypothyroidism that has remained 
undiagnosed. They are identified only after developing complication or following a 
routine health check up. Several women with menstrual disorder or infertility 
attending gynaecology department were retrospectively analysed to have polycystic 
ovaries and / or elevated serum TSH. PCOS and hypothyroidism both together or 
individually adds the risk for infertility and menstrual irregularities. The burden of 
infertility in India is in the ascending trend and the expenditure per birth in infertile 
PCOS women has risen tremendously. Studies conducted in combining these two 
disorders show that they are significantly related. The ultimate finding in PCOS is 
hyperandrogenism which is aggravated in the presence of hypothyroidism. Screening 
for hypothyroidism in PCOS patients in our population gives a better idea about the 
epidemiology of this disorder and the importance of evaluating thyroid function status 
in them. A study conducted by Sridhar et al. also supports the concept of treating 
hypothyroidism first in patients having both these disorders and has found positive 
results by doing so. These facts and findings from various literatures stimulated us to 
conduct a cross sectional study about thyroid function status in newly diagnosed 
PCOS patients by using a single and best indicator of thyroid function status- Thyroid 
Stimulating Hormone (TSH).      
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REVIEW OF LITERATURE 
Polycystic ovary Syndrome (PCOS) is the most common endocrine disorder of 
women in reproductive age group[1,2,3,4]. It is a heterogeneous group of disorder with 
Hyperandrogenism (Ovarian), Hyperinsulinemia & chronic anovulation. The most 
common cause of chronic anovulation and hyperandrogenism is Polycystic ovarian 
syndrome. The term Poly cystic ovary is actually a misnomer, as there are only 
multiple unruptured immature follicles. In 1935, Irving F. Stein and Michael L. 
Leventhal first published a case series of about 7 women with amenorrhoea, 
hirsutism, bilaterally enlarged ovaries, which was later known as POLYCYSTIC 
OVARIAN SYNDROME (PCOS) [5]. The definition of PCOS has undergone 
several revisions and still inconclusive [6] . 
            There are different nomenclatures given for this syndrome [7]:                  
                 1. Polycystic Ovarian Syndrome - PCOS 
                 2. Chronic Hyper-androgenic Anovulation - CHA.  
                 3. Functional Ovarian Hyper-androgenism - FOH 
          The presentation of PCOS in women varies from simple acne to infertility and 
may even be associated with disorders like Diabetes mellitus, Hypothyroidism, 
Dyslipidemia. This shows that the individual’s response to androgen varies i.e ethnic 
variation exists [8]. They are at risk of developing Coronary artery disease, Metabolic 
syndrome, Type 2DM, Endometrial cancer [9,10,11]. More than 50% of the PCOS 
women are obese but can also present as lean individuals. Obese PCOS women have 
higher risk of developing Insulin resistance & Infertility than lean PCOS women. 
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However lean PCOS women have their mean hormones (Androgens, Testosterone, 
Estradiol) levels higher than their age matched controls. 
             This multi-endocrine disorder is more commonly found among teen aged girls 
to early thirties i.e in the early phase of reproductive age of women. Even though 
Hyper Insulinemia, elevated LH/FSH ratios are not included in criteria for diagnosing 
PCOS, many women with this syndrome were found to have associated elevation of 
fasting Insulin, raised LH/FSH ratio. Co-existence of Hypothyroidism in PCOS is 
found in many young girls with menstrual irregularities and infertile women.  
Thyroid hormone sensitivity by ovaries could be explained by the presence of thyroid 
receptors in human oocytes.[12] 
PREVALENCE STATISTICS: 
TABLE : 1 
World [14,15] 3.7-8.6% 
Europe[13] 6.5-8% 
India [1] 5-10% 
Adolescent girls in India  
(15-18yrs)[14, 15] 
9.13% 
Young women in India  
(18-25 yrs)[14,15] 
3.7% 
 
 In UnitedStates, 10% of women visiting Gynaecology out Patient department 
were diagnosed to have PCOS and black women with PCOS showed defect in 
insulin receptor at higher level than white women [2].. 
 Even 20% of normal menstruating women also showed cystic ovarian 
morphology by UltraSonogram [17]. 
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There exists a difference in ethnic response to the same androgen level & that 
seems to be the cause for different level of presentations (acne to Infertility) with 
same androgen level [2,8]. Among pre-menopausal women, about 10% of them with 
glucose intolerance were related to Insulin resistance in PCOS. This suggests that 
regardless of the age PCOS women are at risk of developing NIDDM [22,23]. The 
percentage of PCOS in infertile women has increased to 30%. [14, 18 It is also 
interesting to see that 75% of the women with secondary amenorrhoea fulfil the 
Rotterdam diagnostic criteria for PCOS.[19, 20, 21].  
PATHOGENESIS OF POLYCYSTIC OVARIAN SYNDROME:                 
 The ultimate outcome of the disease is the development of follicles on the 
ovary due to chronic anovulation. The core culprit for anovulation is 
Hyperandrogenism, other factors includes Genetic & Environment. Patients with 
PCOS were found to have menstrual abnormalities from the onset of menarche 
indicating that they have failed to establish a regular menstrual cycle from the onset of 
puberty. Along with cystic ovary, hirsutism, male patterned baldness, skin lesion like 
Acne, seborrhoea are some of the features of Hyperandrogenism [24, 25, 26] leading to 
Polycystic Ovarian Syndrome. The exact or the central pathogenesis is not clearly 
known until now. The alteration in ovarian morphology (cystic) may be due to 
disturbance at any one of the following level: 
1) Hypothalamo-Pituitary-Ovarian axis. 
2) Ovary (local) 
3) Systemic disorder. 
 In Polycystic ovarian syndrome, the site of pathology is at ovary. 
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OVARY: 
Anatomy & development: 
Ovary, the female gonad, lies in ovarian fossa, one on either side of the lateral 
Pelvic wall. In nullipara, the long axis of the ovary is vertical but in multipara It is 
horizontal. In young girls before puberty the ovaries are Greyish pink & smooth. 
After puberty, it becomes Grey & have uneven surface. Each Ovary has 2 poles, 2 
borders, 2 surfaces. It is divided into outer cortex & inner medulla. After puberty, the 
Cortex at any time shows various stages of development of Graffian follicles. Medulla 
has no anatomical and physiological significance. The fallopian tube is proximal to 
ovary. Ovum released during every menstrual cycle is picked up by the fallopian tube. 
If fertilisation takes place embryo is formed if not normal menstruation occurs [27,28].  
Ovary is formed from genital ridge which is formed from the coelomic 
epithelium. Cords of cells proliferates from this germinal epithelium (coelomic) and 
forms mesoderm (Sex cords). Primordial germ cells of yolk sac, migrates to ovarian 
region & give raise to OOCTES. Sex cords are broken into small masses which is 
enveloped by primordial germ cells that gives rise to PRIMORDIAL FOLLICLE. 
Later, sex cords are replaced by cortical cords which give rise to FOLLICULAR 
CELLS of ovary. Developmental arrest of the ovarian follicle may result in the 
formation of one or more small cyst called ovarian cysts. Occasionally, ovary may 
also possess Thyroid tissue or Adrenal tissues [29].     
7 million primordial follicles are present at the time of fetal growth. But at 
birth, only 2 million ova are present and the remaining follicles undergo attrition. This 
2 million ova enters 1st meiotic division but gets arrested at prophase. At the time of 
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puberty only 3, 00,000 ova are available and are called PRIMARY OOCYTES. 
Others get atrophied by apoptosis. 
Throughout the reproductive period of every woman, approximately 500 ova 
are shed during ovulation. One ovum per menstrual cycle and the others are atrophied. 
At the time of ovulation they complete the 1st meiotic division. This ovum released 
during ovulation is the SECONDARY OOCYTE. If fertilisation occurs 2nd meiotic 
division proceeds otherwise they are arrested in metaphase and are released [30].                            
Functions of Ovary: 
1) To ovulate single matured ovum during every menstrual cycle. 
2) To secrete Sex hormones (Androgen and estrogen & Progesterone).  
A normal menstrual cycle, starts from 1st day of the current cycle to the 1st day 
of the next cycle usually about 28 days, but varies (25-35 days). Menstruation lasts for 
3-5 (range1-8) days. Average bleeding is about 30mL (upto 80 mL). 
         According to one theory, the onset of menstruation is due to lysosomal 
membrane leak in the endometrial tissues releases some enzymes. This helps in 
formation of Prostaglandin from cell membrane phospholipid. The Prostaglandins 
produced causes local inflammatory changes like vasospasm, endometrial necrosis, 
bleeding and shedding of endometrial mucosa. [31]  
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PHASES OF MENSTRUAL CYCLE: 
1) MENSTRUAL PHASE:                 
       The first phase in the cycle, during which shedding of mucosa & bleeding 
takes place. 1st - 5th day. 
2)  PROLIFERATIVE/FOLLICULAR/PRE-OVULATORY-PHASE:     
The second phase starts from 5th – 14th day of the cycle. This is the estrogen 
predominant part. The endometrium proliferates, new blood vessels are 
formed, Follicles starts maturing. 
OVULATION: occurs on 14th day. 
3) SECRETORY / LUTEAL:             
The third phase of the cycle from 14th day- 28th day of the cycle. In this Post-
ovulatory situation, Corpus luteum is formed which produces Progesterone.           
OVARIAN CYCLE: 
In the beginning of the cycle, several follicles on the ovarian surface start 
enlarging & forms sac filled with follicular fluid. In human, one of the follicles starts 
growing rapidly and by 6th (5-7) day it forms the DOMINANT FOLLICLE. The 
dominant follicle selection seems to be related to the ability of the follicle to secrete 
sufficient estrogen, that is needed for final maturation. 
A matured Graffian follicle has Theca externa & Theca interna just below its 
capsule. Under Theca interna is the granulose cell layer that has FSH receptor. It 
secretes estrogen, under the influence of FSH released from the Anterior pituitary. 
Theca Interna cells has LH-Receptor that secretes Androstenidione (Androgen). This 
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androgen from the Theca interna enters in to the granulose cells where it gets 
aromatised to Estradiol [32,].   
REGULATION OF OVARIAN CYCLE: 
Hypothalamus, the triggering centre for hormone synthesis, release 
Gonadotropin Releasing Hormone (GnRH) in pulse. Anterior pituitary has 
gonadotrophs in which receptor for GnRH is present. Luteinizing Hormone (LH) & 
Follicular Stimulating Hormone (FSH) are the stimulating hormones released from 
anterior pituitary. Granulosa cells of ovary has receptor for FSH, Theca interna has 
receptors for LH. FSH stimulates the growth & early maturation of graffian follicle 
which in turn secretes estrogen to the maximum level. LH surge takes place 36 hrs 
just before ovulation. Frequency of GnRH secretion is activated by Estrogens but 
inhibited by Testosterone & progesterone. GnRH stimulates the production of LH.               
              During the early part of follicular phase in menstrual cycle Estrogen is 
produced in moderate amount which acts on negative feedback centre situated in 
medial hypothalamus, LH is not produced now. But in late follicular phase estrogens 
are produced in excess and that stimulates the positive feedback centre in anterior 
hypothalamus inducing LH production. This production reaches the peak just 36-
48hrs before ovulation called mid-cycle LH surge [28, 32].             
After ovulation, corpus luteum is formed it secretes mainly progesterone and a 
very little amount of estrogen. Progesterone predominates estrogen in the luteal phase 
and plays a vital role in pregnancy, if fertilization takes place. If not, it favours the 
Prostaglandin formation and proceed towards menstruation.           
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FSH:  (Follicular Stimulating Hormone) 
It is a glycoprotein dimer, about 35.5KD. It has 2 polypeptide subunits α & β. 
Like the α subunits of other hormones (LH, TSH, hCG), it is not specific. The β 
subunit is more specific for its biological actions and binding with its (FSH) receptor. 
The t½ is 3-4 hrs [34]. Serum level varies to the phase of the cycle. 
Reference Interval: [33] 
Follicular: 1.4- 9.9 mIU/mL 
Mid-cycle peak: 0.2-17.2 mIU/mL 
Luteal: 1.1-9.2 mIU/mL. 
LH (Luteinizing Hormone): 
Also known as Lutropin/ Lutrophin. It is a heterodimeric glycoprotein. Each 
monomer has one α and one β subunit not covalently associated. The structure is 
similar to other glycoprotein hormones. The β subunit is specific for its biological 
function. Its t ½ is 20 min. Serum normal level for normal menstruating young 
women varies according to her phase of menstruation.[34] 
Reference Interval [33] 
Follicular : 1.7-15.0 mIU/mL 
Mid-cycle peak: 21-56.6 mIU/mL 
Luteal: 0.6-16.3 mIU/mL.   
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GnRH: (Gonadotropin Releasing Hormone) 
 Also known as Luteinizing hormone Releasing Hormone (LHRH), It is a 
trophic peptide hormone, synthesised and released from GnRH neurons within  
pre-optic area of the hypothalamus. It occupies the first step in maintaining 
hypothalamo-pituitary-gonadal axis. They act through GnRH Receptor, a seven 
transmembrane G protein coupled receptor that stimulates phosphoinositide 
phospholipase C which mobilizes calcium & protein kinase C, this activates protein in 
the synthesis of GnRH. It has 2 seperate feedback centres in hypothalamus as 
mentioned earlier, positive & negative feedback centre.  
SYNTHESIS OF SEX STEROID HORMONES IN FEMALES:[35, 36, 37]   
SEX HORMONES: ANDROGEN              
                                ESTROGEN                 
                                PROGESTERONE 
ANDROGEN: (DHEA, DHEAS, TESTOSTERONE) 
Ovarian (Theca cells): Androstenidione, Testosterone.    
Ovarian source contributes to 25% of circulating Testosterone, 50% of 
androstenedione, and 20%of DHEA. The marker of ovarian androgen is 
Testosterone. 
 Function : Undergoes Aromatisation & Estrogen production and its biological effect.   
Adrenal (Zona reticularis): Dehydroepiandrosterone and its sulphated form. 
 Adrenal gland contributes to 80% of DHEAS and DHEA, 50% of 
Androstenedione, and 25% of circulating Testosterone. It is correctly known as 
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didehydroepiandrosterone. It is the most abundant endogenous steroid hormone in  
human [30] produced by adrenal gland, gonad & brain. It is an intermediate in the  
biosynthesis of androgen and estrogen. It has a variety of biological effects like  
binding with its receptor, acting as neurosteroid [38] DHEA and DHEAS are not  
produced by the ovaries . The marker of Adrenal androgen is DHEA. Adrenal 
androgen is under the control of anterior pituitary (ACTH).                              
 Function: Pubic hair & axillary hair growth (secondary sexual characters)        
MOLECULAR SITE: MITOCHONDRIA                 
Cholesterol is the essential molecule for all steroidal compound synthesis and 
is supplied from (Lipoproteins) LDL Cholesterol or by de novo synthesis. This 
cholesterol which is in cytoplasm moves from the it and is transported to the inner 
mitochondrial membrane by a special transport protein called StAR –Steroidogenic 
Acute Regulatory Protein. The rate of steroid synthesis depends on the rate of entry of 
cholesterol into mitochondria rather than the Rate limiting enzyme (11α OH lase) 
[39,40]. Steroid synthesis takes place mainly in the gonads (Ovaries in female & testes 
in male) and to some extent in the adrenals. 
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TESTOSTERONE: (C19H28O2)   
It is a C19 steroid is the principle androgen in men but also produced in 
female. Peak production is 4:00-8:00 am with a nadir between16:00-20:00hrs [41, 42]. 
Active form is Dihydrotestosterone (DHT) & its formation takes place in skin & 
prostate (male). Aromatisation of testosterone to estrogen takes place in many tissues 
particularly in liver and adipose tissues. Only 2-3% of Testosterone circulates freely 
in blood others are protein bound.[43] Sex Hormone Binding Globulin(SHBG) has high 
affinity but low capacity to bind testosterone (66-78%), and is the tightly bound form. 
Albumin has high capacity for binding Testosterone but with low affinity (20-30%) 
and is the weakly bound form [44, 45]. 
Reference Interval [51]: 
Total Testosterone Adult (F): 15-70 ng/dL. 
**Testosterone level > 60 ng/dL is more consistent with PCOS [47] 
 Free Testosterone Adult (F): 1.0- 8.5 ng/dL                                                       
Bioavailable Testosterone 
It is the biologically available testosterone and includes both free and Albumin 
bound form and usually accounts for 35% of the Total Testosterone [41,42]. Albumin 
bound form easily gets disassociated from it and is available for tissue uptake. So, 
bioavailable testosterone correlates with free testosterone. [48, 49, 50]  
Reference Interval: [51]  
Bio available Testosterone Adult (F): 0.6-5.0 ng/dL. 
The serum level of sex steroids shows a pattern of spiking i.e.  
       -  It has a peak in utero by 7th week of gestation-comes to baseline at birth 
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       -  Shows again a peak by 2-3 months after birth 
       -  Goes to very low level till puberty. 
ESTROGEN [28,33]: 
SOURCE: Granulosa cells of Ovary, Corpus luteum, and Placenta.   
The parent compound for estrogen is Estrane: C18 compound with methyl group at 
C13 and aromatic ring A. All estrogen has a hydroxyl group attached at C3. 
VARIOUS FORMS: E1, E2 & E3                
           E1: Estrone (Ketone group at C17) 
           E2: Estradiol (Hydroxy group at C17) 
           E3: Estriol.            
Functions: 
a)  Growth of graffian follicle, growth of female reproductive tract, breast.   
b)  Increases secretion of Thyroid binding globulin & Angiotensin,        
c)  It reduces cholesterol.        
d)  They are essential for female body configuration i.e. distribution and 
deposition of fat in female.  
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Theca Interna (ovary) is the site of androgen production and this androgen is 
transported down to granulose cells for aromatisation and gets converted to estrogen . 
Androstenedione is either directly converted into Estrone by aromatase or indirectly, 
gets converted into Testosterone by 17β-OH steroid dehydrogenase, then converted to 
17-β Estradiol by aromatase. 17β Estrdiol is the most biologically active form of 
estrogen [40]. All sex steroids ( progesterone, androgens & estrogens ) are produced by 
ovary but because they lack in 21α-OH lase & 11β-OH lases, they do not produce 
other steroids like mineralocorticoids and glucocorticoids.  
Reference Interval[51]: 
12-17 yrs: 40- 410 pg/mL 
Adult Female: 
Early follicular phase: 20-150 pg/mL 
Late follicular phase: 40-350 pg/mL 
Mid-cycle: 150-750 pg/mL 
Luteal phase: 30-450 pg/mL 
In both sexes, sex steroids are transported through SHBG (α globulin) & 
Albumin. SHBG has high affinity to bind steroids; Albumin has high capacity to bind. 
  16
In female, SHBG bind 66-78% of testosterone & 40-60% of Estrogen. Albumin binds 
20-30% of testosterone & 40-60% of Estrogen. A very minute amount 2-3%circulates 
freely (unbound).  
SEX HORMONE BINDING GLOBULIN:[52, 53, 54, 55]             
               A homodimeric glycoprotein having 2 laminin G (LG) domain joined by a 
linker region. This LG domain serves like a pocket for steroid binding. The serine 
residue in the pocket binds with different steroid at different points androgen to A 
ring, estrogen to D ring. Sugar are attached at 2 different sites by N- glycosylation on 
Asparagine and 1 O-glycosylation on Threonine. SHBG is produced mainly by the 
liver other organs are brain, uterus, testes & placenta. Binding affinity for steroids are 
in the order of DHT> testosterone> androstenediol> estradiol> estrone. 
Bioavailability of sex hormones are influenced by SHBG. SHBG is influenced by 
factors like other plasma proteins. SHBG is increased in pregnancy, oral 
contraceptives, Hyperthyroidism.  
SHBG is decreased in Hypothyroidism, obesity and liver diseases.       
Causes of Increased SHBG 
 Estrogens 
 Thyroid hormone 
 Pregnancy 
 Estrogen-containing preparations 
Causes of Decreased SHBG  
 Androgens 
 Synthetic progestins (norethindrone, norgestrel, desogestrel, 
norgestimate) 
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 Glucocorticoids 
 Growth hormone 
 Insulin 
 Obesity 
 Acromegaly 
 Hypothyroidism 
 Hyperinsulinemia  
CHANGES IN HORMONES TOWARDS PUBERTY: [56, 57, 58]:    
 -  Cortical androgen stimulating hormone starts elevating in both sexes. 
-  Hypothalamus and pituitary shows resistance to the negative feedback 
given by estrogen. 
 -  GnRH is released in pulse in night. 
-  GnRH-stimulates LH, FSH production till it reaches adult level. 
- Through FSH, it stimulates- ovaries to produce estrogen - stimulates –
graffian follicle growth, uterus growth, breast development. 
- These physiological & biochemical changes continues and accumulates 
in menarche –the beginning of first Menstrual period. 
Usually adrenarche precedes puberty, adrenal androgen begins to increase by 6-7 yrs 
in girls[43].  
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HYPERANDROGENISM :                   
The sources of Androgen may be from Ovary, Adrenal gland, & Peripheral 
conversion. 
CAUSES OF HYPERANDROGENISM [59] 
LOCAL: 
 1. Adrenal gland related: Hypersecretion / Tumor. 
 Congenital Adrenal Hyperplasia (CAH) 
 Non-classical CAH 
 Tumor of Adrenal 
 Cushing’s syndrome.            
  2. Ovary related: 
 Polycystic Ovarian syndrome 
 Tumor arising from Theca cells 
SYSTEMIC CAUSE: 
 Hypothyroidism 
 Hyper-insulinemia. (Insulin Resistance)  
 Hyperprolactinemia.                
IN PCOS: 
The proposed & accepted concept for ovarian hyper-androgenism is Cortical 
stromal Hyperplasia / Stromal hyper-thecosis (Hyper-cellular thecal layer) [60, 61, 62]. 
Theca cells of graffian follicle has receptor for LH and produces androgen. It not only 
produces andogen but also Activin & Inhibin-B. Activin, an activator or stimulator of 
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FSH. In PCOS, hyperplasia of thecal layer of ovary produces excess amount of 
androgen and Inhibin B.  
Inhibin B [63]:    
 It is a non steroidal protein hormone having α & β subunits. It inhibits FSH 
production but stimulates LH from Anterior pituitary. The mechanism by which it is 
stimulates LH is not known. Inhibin is produced from ovary, pituitary gland, placenta, 
corpus luteum and other organs. Inhibin B is now used as the marker of fertility in 
both male and female. 
 Together with suppression of FSH by Inhibin, estrogen synthesised from 
excess androgen (by aromatization) also gives negative feedback inhibition to FSH. 
Stimulation of LH and inhibition of FSH collectively leads to increased LH/FSH ratio 
even in the follicular phase which is against the normal physiology. FSH hormone is 
the predominant one in the follicular phase and expected to be high when estimated 
during these days (usually D2-D3).          
 Low FSH from anterior pituitary is not sufficient enough for the growth of 
graffian follicle and there is no dominant follicle formation. Prolonged suppression of 
FSH & peaking of LH leads to chronic anovulation and formation of number of small 
Immature, unruptured follicle filled with fluid (follicular fluid). Multiple immature 
follicles found on the surface of the ovary give the picture and hence the terminology. 
POLYCYSTIC OVARIAN DISEASE.  
 Hyperthecosis with multiple cysts causes enlargement of ovary, increases 
volume and stimulates fibrosis of the stromal layer and capsule. As there is no 
ovulation, corpus luteum is not formed and no Progesterone production. Occasionally, 
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prolonged exposure to high estrogen level causes hyperplasia of endometrium and 
shedding of them causing irregular menstruation. 
There is a conflict over the concept that there exists or not in the defect of 
central ovarian axis (Pituitary-Ovarian axis). Most of the scholars do not accept this 
view because, many interventional studies have proved that Wedge resection of ovary 
has shown to restore the normal ovarian cycle. From this, it is also confirmed that it is 
only the ovarian androgen, the key cause for hyperandrogenism that has obstructed 
the normal ovarian cycle [46].                
The overall effect is defect in development of ovarian follicle and induced 
premature ovarian atresia. Together with the above findings in the ovary, when 
patients have the below mentioned clinical features, then the complex disorder is 
called POLY CYSTIC-OVARIAN SYNDROME. This finding in ovaries of women 
having PCOS blends with the finding in ovaries of post menopausal Women where 
the ovarian reserve is lost [64]. 
MORPHOLOGY OF POLYCYSTIC OVARY:                   
The morphology of the ovary changes from smooth, soft pinkish structure to 
enlarged pearly white, firm encapsulated organ. The number of primordial follicles 
are found to be the same but the number of growing follicles are increased. Each 
ovary contains more than 50 cysts. On cut section, it shows increased cortical 
thickening with number of cystic follicles.             
ANOVULATORY CYCLES  
This is usually seen in the early months of onset of puberty & / few months 
prior to menopause where normal menstruation takes place without ovulation . 
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Prolonged an-ovulation alters the normal menstrual cycle. The length of the cycle 
prolongs more than 35 days. Secretary phase / Luteal phase is always constant of 
about 14 days but Proliferative phase may vary. Any change in the length of 
menstrual cycle is only because of the variation in the proliferative phase [65]. 
In anovulatory cycles, the graffian follicle does not attains maturity as 
expected and is not ruptured. This immature follicles formation if continues, then it 
results in multiple follicles on the surface of the ovary along with enlargement of the 
ovary volume called POLY CYSTIC OVARIAN DISEASE where chronic 
anovulation and multiple cysts in the ovary is seen. The anovulatory cycles alters the 
hormone levels particularly the estrogen and Androgens (Testosterone) which remains 
elevated and is the important cause of infertility. 
CAUSES OF ANOVULATION [66-75]: 
Hormone Imbalance(70%)    
 Hypothalamus: Any disturbance in the Hypothalamo-pituitary-ovarian axis 
alters the regular menstrual cycle. 
 Pituitary: Tumor / Dysfunction 
 Ovarian: Polycystic ovarian syndrome. 
 Systemic. 
Ovarian:  
Polycystic ovarian syndrome, the leading cause for anovulation in women 
going to infertility clinic. Up to 90% of cases of anovulation are by PCOS and is 
usually hereditary[72]. Anovulation in PCOS is disturbance in the normal ovulating 
menstrual cycle. The abnormal antral follicles are formed due to immature follicle not 
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able to rupture leading to anovulation. Elevated insulin also stimulates theca cells to 
increase production of androgen via Insulin like growth factors. This again arrest 
follicular development resulting in anovulation. 
 Systemic causes: 
1) Hypothyroidism. 
2)  Hyperprolactinemia. 
Functional cause : 
1) Anorexia. 
2) Stress. 
3) Obesity . 
HYPOTHALAMUS 
 
PITUITARY                   ANOVULATION                        OVARIAN 
                   
                FUNCTIONAL                 SYSTEMIC DISORDER 
AGE, NUTRITION,           1. HYPOTHYROIDISM 
OBESITY, SMOKING,        2. DIABETES MELLITUS 
INFECTION, DRUGS         3. AUTOIMMUNE 
4. HYPERPROLACTINEMIA 
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HYPERINSULINEMIA[76-78] :  
In 1921, Achard & Thiers first described the association of Carbohydrate 
metabolism with hyperandrogenism as “the diabetes of bearded women’’. In 1947, 
Kierland et al, reported the skin lesions Acanthosis nigricans occurs frequently in 
hyperandrogenism & Diabetes mellitus [22].       
Elevated Insulin level is a very common finding in PCOS patients though it is 
not included in diagnostic criteria. Insulin is not only a hormone of metabolic pathway 
but also has an important role in reproductive cycle. About 70-80% PCOS patients 
were found to have Insulin resistance. According to a study conducted by the 
Endocrine society of India, on PCOS women 23-35% were in Impaired Glucose 
Tolerance (IGT) state and 4-10% had Type2 DM which are seven fold higher than 
their age matched normal women. Indian women show difference in response to 
glucose tolerance than white women. Obese women particularly truncal obesity 
showed higher level of glucose intolerance than lean women but still lean PCOS 
women have higher intolerance when compared with their age matched Controls. 
Burghen et.al showed the association between Insulin resistance in PCOS women. He 
found a high positive Correlation among Insulin and sex steroids like androstenidione, 
testosterone in Polycystic ovarian syndrome patients [79] Ehrmann et.al, demonstrated 
that those patients having dysfunction of beta cells of pancrease are at risk of 
developing carbohydrate intolerance and Type 2 Diabetes mellitus among PCOS 
women.    
Hyper-insulinemia may be due to increased production of insulin or reduced 
uptake of insulin by the peripheral tissues. The peripheral uptake is called clearance 
and is receptor mediated. Any defect in the number and or function of the receptor 
  24
causes decreased clearance of Insulin by the tissue. In PCOS, there is reduced 
clearance leading to Hyper-Insulinemia.[80, 81] but a little higher level of secretion by 
beta cells also happens. 
 Insulin Resistance [82, 83]:  
Is the diminished biological response of the body below the normal level to 
the available insulin. This diminished response may be due to decreased sensitivity or 
decreased maximum responsiveness or both.  
Peripheral resistance which is quantitated by Euglycemic glucose clamp test. 
In this test a known quantity of I.V glucose and I.V basal insulin is given 
simultaneously and serial arterial blood collection is done. The amount of glucose 
given by I.V equals the amount of glucose taken up by the peripheral tissue, . This 
phenomenon of peripheral uptake is called Insulin Mediated Glucose Disposal 
(IMGD), more essential in skeletal muscle uptake than in liver or adipose tissue. 
Euglycemic glucose clamp test is reduced in PCOS up to a level of Non-Insulin 
Dependent Diabetes Mellitus indicates that there is reduced peripheral uptake. 
Obesity in PCOS has synergistic negative effect in hepatic glucose production - an 
important factor for Insulin resistance. Body fat has higher negative effect in Insulin 
sensitivity in PCOS women [58,59].  
Molecular view of Insulin resistance shows:                   
1) Pre-Receptor – Antibody mediated. 
2) Receptor 
3) Post receptor signalling pathway – PCOS level of resistance.        
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Insulin Receptor [84-89]: 
It is a cell surface hetero-dimeric receptor with 2α and 2β subunits joined by 
disulphide bond. The 2α subunits has the N terminal ends, hanging outside of the cell 
surface and has the ligand binding domain. The 2β subunits spans on the cell 
membrane and extents intracellularly. It has the C terminal ends. The β subunit has 
intrinsic Tyrosine kinase activity and stimulate auto phosphorylation of its own 
certain tyrosine residue when the substrate binds.  
Insulin Receptor belongs to a subfamily of protein tyrosin kinase receptor. Its 
phosphorylation converts it into an activated receptor. This activated (phosphorylated) 
receptor in turn phosphorylates intracellular substrate to initiate the signalling 
pathway. The first substrate identified was Insulin receptor substrate complex IRS-1, 
later IRS-2, IRS-3 were identified which binds to intracellular signalling substance 
phosphotidyl inositol3 phosphate kinase (PI3-K) leading to Insulin mediated glucose 
transport.  
Insulin has a number of target tissue action like growth regulation, gene 
expression regulation, etc. Now it seems that Ras-Raf MEK pathway regulates growth 
PI3-K pathway in glucose uptake. But the termination of this signal is not completely 
known.It is seems to be the phosphorylation of serine residue instead of tyrosine that 
terminates the signal in EGF and other kinases, which may be the one that cause 
termination in Insulin Tyrosin kinase through Protein kinase C (PK-C). This is the 
step where the signalling pathway is disturbed and Insulin resistance is noted.  
Insulin role in glucose metabolism is impaired in resistance but insulin 
induced androgen synthesis is intact which is paradoxical. The overall effect of hyper-
insulinemia is Hyerandrogenism by decreasing hepatic Sex Hormone Binding 
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Globulin production . The protein bound androgen is reduced there by free androgen 
is elevated which causes the features of hyperandrogenism seen in PCOS women. 
GENETIC FACTOR [90-92]:            
It has a significant contribution to etiology as studies have prooved different 
levels of response to the same level of androgen level among different ethnic group. It 
runs in families siblings, mother, maternal aunt have the history of menstrual 
irregularities or treatment for Infertility have PCOS features on retrospective analysis. 
United Kingdom studies showed men with elevated LH/FSH ratio found to have 89% 
of their daughters with PCOS. The inheritance pattern is supposed to be Autosomal 
Dominant. In all the sub ship, 80% female were affected. Givens and associates from 
university of Tennessee have reported multiple PCOS kindreds, showing members in 
several generations 
ENVIRONMENT [93]:         
This factor also exists in the pathogenesis. Obesity alone plays an important 
role in etiology. Fatty diet, more intake of simple sugar or increased endogenous 
production of fat- all contributes to elevated fat in blood which is directed towards 
steroid genesis.  
CRITERIA FOR PCOS [94, 95]: 
 In 1990, National Institute of Health (NIH) consensus workshop defined 
PCOS as chronic anovulation with clinical & / Biochemical hyperandrogenism, with 
exclusion of other mimicking etiologies like thyroid, Adrenal dysfunctions. 
  In 2003, the European Society for Human Reproduction / American Society of 
Reproductive Medicine (ESHRE/ASRM) conducted a workshop in Rotterdam 
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proposed that to diagnose a women with PCOS 2 out of 3 of the following should be 
satisfied 1. Oligomenorrhoea & / anovulation, 2. Clinical&/Biochemical 
hyperandrogenism and 3. Polycystic ovaries on Ultra sonogram.   
Other etiologies should be excluded. Some argued that this expanded 
Rotterdam criteria may over diagnose or misdiagnose PCOS. 
In 2009, the Androgen excess & PCOS (AE-PCOS) society published a report 
emphasizing that PCOS is primarily a hyperandrogenism disorder and proposed for 
revision in the definition of hyperandrogenism and ovarian dysfunction, there by 
encompassing the Rotterdam ultrasonogram criteria but requiring hyperandrogenism 
for diagnosis. 
In all the above said societies, they don’t separate the criteria for Adolescent 
girls. But some authors says that the criteria proposed for adults poses diagnostic 
problem as the characterestics of normal puberty overlaps  with features of PCOS. So, 
some have proposed criteria for adolescent girls and are much stricter than for adult. 
Sultan and Paris: Adolescent girls should meet 4/5 of following criteria [96] 
1) Oligomenorrhoea or amenorrhoea > 2 years after menarchy. 
2) Clinical hyperandrogenism. 
3) Biochemical hyperandrogenism. 
4) Insulin Resistance / hyperinsulinemia. 
5) Polycystic ovaries in ultra sound. 
Carmina & colleagues suggested applying Rotterdam criteria but limiting 
definitive diagnosis to adolescent girls only who meets all three criteria [97, 98]. But 
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adolescent girls PCOS criteria are not endorsed currently by the panel or society in the 
field. They too have limitation of inappropriate early diagnosis.    
Even though there are a number of definitions, the Rotterdam consensus is the 
most widely accepted one across Asia, Europe and Australia and is used for 
guidelines. Recently, in October 2013, the Endocrine society released a practical 
guidelines to diagnose and treat PCOS which emphasise to use Rotterdam Criteria for 
diagnosis.  
REVISED ROTTERDAM CRITERIA 2003[99]:  
(DIAGNOSTIC CRITERIA FOR POLYCYSTIC OVARIAN SYNDROME) 
Two of the following three criteria are required: 
1. Oligomenorrhoea / Amenorrhoea. 
Oligomenorrhoea: Cycle >35 days / < 8 cycles per year. 
Amenorrhoea: Absence of cycle for 6 months who was menstruating regularly 
2. Hyperandrogenism: Clinical / Biochemical 
Clinical: Acne / Hirsutism / Alopecia / Male pattern baldness. 
Biochemical : Serum Androgen (Testosterone) is elevated. 
3. Polycystic ovaries on Ultrasound 
>12 cysts, each 1-2mm diameter in the periphery of the Ovary giving Pearl 
necklace appearance. 
Other etiologies should be excluded such as Congenital Adrenal hyperplasia, 
Adrenal tumors, Cushing syndrome, thyroid dysfunction, hyperprolactinoma.     
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Some authors have given major and minor criteria for diagnosing PCOS in which 
USG finding of polycysts is considered only as minor criteria. 
TABLE : II 
 
CLINICAL PRESENTATIONS: 
1) MENSTRUAL IRREGULARITY: Oligomenorrhoea / Amenorrhoea. 
2) METABOLIC FEATURES: Obesity, Dyslipidemia, Diabetes mellitus. 
3) ACNE. 
4) HIRSUTISM. 
5) ALOPECIA. 
6) ACANTHOSIS NIGRICANS. 
7) INFERTILITY. 
MENSTRUAL IRREGULARITY [100, 101]:           
The most common presentation is oligomenorrhoea & / amenorrhoea, usually 
secondary amenorrhoea but also present as primary amenorrhoea. Some may not have 
MAJOR CRITERIA MINOR CRITERIA 
Chronic anovulation,Clinical signs of 
androgen excess Hirsutism Acne 
Alopecia Menstrual disturbance  
Infertility, Virilization, Exclusion of 
alternative causes of androgen excess. 
Exclusion of alternative causes of 
androgen excess 
Onset at puberty 
Insulin Resistance, 
Elevated LH:FSH ratio (> 2.5–3) 
Ultrasonographic evidence of polycystic 
ovaries 
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menstrual irregularities at all. Prevalence of amenorrhoea is 5% in general population 
and 8.5% in post pubertal adolescent population. 
Primary Amenorrhoea: 
A condition in which a woman had never had menstruated so far. 
Secondary Amenorrhoea:        
  Cessation of cycle at least for 6 months in a woman who had previously 
normal cycles (75%). After excluding pregnancy, secondary amenorrhoea may be 
caused by ovarian dysfunction, uterine dysfunction, adrenal, thyroid disorders, 
pituitary, Hypothalamus dysfunction, psychological stress. It is classified into 2 
groups either with or without accompanied hyperandrogenism. PCOS is the ovarian 
cause for amenorrhoea with hyperandrogenism. 
Oligomenorrhoea: Prolongation of menstrual cycle > 35 days / < 8 cycles per year. 
HIRSUTISM [102-105] :           
  It is defined as excess growth of terminal hair on androgen sensitive area. It 
includes chin, upper lip, sternum, periareolar region, sideburns, umbilical, sacral and 
pubic region. Hirsutism is different from hypertrichosis / vellus in which thin hair is 
distributed throughout body & face & are depigmented. Hirsutism involves medulla 
of hair, thick and pigmented. 
Mechanism of Hyperandrogenism causing Hirsutism: 
In hirsutism, there is increased sensitivity of the hair follicle to normal level of 
circulating androgen and this causes excess hair growth. Androgen through androgen 
receptor in dermal papilla has strong effect in hair growth. Any defect of the androgen 
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receptor results in hirsutism. It has opposite effect in hair follicle of scalp and the 
follicle in body & face. Androgen stimulates the body & face hair but inhibit hair 
growth in the scalp causing alopecia (male pattern baldness). 
         Idiopathic hirsutism – accounts for 6-50% of hirsutism. 
         Non-Neoplastic hirsutism - occurs at puberty.  
         70-80% hirsutism were affliated with PCOS.                  . 
ALOPECIA [106]:          
Hair loss in excess is a very rare presentation in PCOS women. 
ACNE:[102, 106, 107] :  
A common pre menstrual finding in most of young girls. Severe cystic 
comidones, painful and persisting is a typical in androgen dependent. Androgen have 
profound effect on skin, its appendages, sebaceous gland and hair follicle, strongly 
depends on biologically active androgen. In sebaceous gland, it stimulates sebocyte 
proliferation particularly in the face and leads to increased sebum secretion. Within 
the intra follicular duct of the pilo-sebaceous unit, androgen increases the rate of 
mitosis and epithelial proliferation, leading to hyperkeratosis.  
4 key factors for Acne    
 Increased sebum production. 
 Follicular hyperkeratinisation. 
 Colonisation of the pilosebaceous unit with propioni bacterium acnes. 
 Production of inflammation. 
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OBESITY [108, 109, 110]:        
It is increased deposition of adipocytes in the body.35-80% of PCOS women 
presents with obesity, particularly central / truncal obesity. Obesity assessment is by 
BMI & waist Hip ratio. 
 ACANTHOSIS NIGRICANS [22]:  
A reddish black, thick, velvety lesion on the skin around the neck. It is an 
external marker of Insulin Resistance. Also found in other auto-immune disorders. 
METABOLIC FEATURES:  
Alteration in lipid profile, elevated cholesterol, LDL, Triglycerides are 
commonly found. In spite of increased level of Insulin, the tolerance to glucose is 
diminished to an extent that it may lead to NIDDM.[76,77] Incidence of Hypertension 
and Diabetes among postmenopausal women showed higher rate in those who had 
PCOS in their early age. 
INFERTILITY [109-115]:           
WHO defines infertility as inability of a woman to conceive after one year of 
unprotected intercourse (and there is no other reason, such as breast feeding or 
postpartum amenorrhoea)[109]. Infertility also refers to the state of a woman who is 
unable to carry a pregnancy to full term. The definition varies by different 
international organizations.                
The consequences of infertility are manifold and includes societal 
repercussions and personal suffering. Infertility may have profound psychological 
effects. In many cultures, inability to conceive bears a stigma. More than 50% of 
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women visiting Infertility clinic were found to have PCOS. Chronic anovulation, the 
major cause for female infertility in PCOS women.  
Primary Infertility: 
  Couple without any successful pregnancy so far. 
Secondary Infertility:     
A woman who had conceived previously but unable to conceive currently. 
Subfertility: 
Defined as less fertile than a typical couple.             
The distribution of infertility [111]: 
1/3 – Female infertility, 1/3 – Male Infertility, 1/3 – Unknown. 
  Female infertility is around 48 million women, and varies according to 
geographical location. In 2010, there was an estimate of 48.5 million infertile couples 
Worldwide, highest rate regions included Eastern Europe, North Africa, the middle 
East, oceania, and Sub-Saharan Africa [114]. 
   According to the American Society for Reproductive Medicine (ASRM), Age, 
Smoking, Sexually Transmitted Infections, and being overweight or underweight can 
all affect fertility in women [108]. 
CAUSES OF FEMALE INFERTILITY:  
Chromosomal disorders, 
Anatomical & congenital defects in female reproductive system, 
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1. The most common cause is ANOVULATION 
2. Functional disorders, 
3. Genitic & Environmental factors 
ANOVULATION : 
CAUSES: 
  Hormonal imbalance     
   Hypothalamo-Pituitary-gonadal axis disturbance  as mentioned early. 
                        Systemic disorders. 
 Functional disorders.               
OVARIAN CAUSE (Major) of anovulation: [116, 117] 
Female infertility caused by anovulation is called "anovulatory  infertility", as 
opposed to "ovulatory infertility" in which ovulation is present [91] and they will have 
normal menstruation. The most common ovarian cause for anovulation is 
PolyCysticOvarianSyndrome (PCOS). 
SYSTEMIC CAUSES of anovulation: 
1. Thyroid gland disorders: 
Thyroid gland dysfunction both hyper and hypothyroidism causes menstrual 
problems. It alters the balance of reproductive hormones.  
2. Diabetes mellitus 
3. Auto-immune disorders.            
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FUNCTIONAL DISORDERS (10-15%): 
AGE:  
Woman’s fertility is affected by her age. About 80% of the cycles 
are anovulatory in the first year of menarche, 50% up to three years and 10% till sixth 
year [83]. A woman's fertility peaks in early and mid 20s, after which it starts 
declining, and this declination accelerated after 35 yrs of age. For women aged 35, 
about 94 out of every 100 who have regular unprotected sexual intercourse get 
pregnant after three years of trying. For women aged 38, however, only 77 out of  
every 100 do so. This proved that the fertility of a woman decreases as her age 
increases.  
SMOKING:         
Cigarette smoking interferes with folliculogenesis, embryo transport, 
endometrial receptivity, endometrial angiogenesis, uterine blood flow and the uterine 
myometrium. 
SEXUALLY TRANSMITTED DISEASES:  
This one of the leading causes of infertility. 
NUTRITION & OBESITY:  
About 12% cause of infertility are due to nutrition a woman either 
being underweight or overweight. Fat cells also produces estrogens by aromatization, 
in addition to the primary sex organs. Too much body fat deposition causes 
production of excess estrogens (hyperestrogenism) and the body begins to react as if it 
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is on birth control (OCPills), limiting the odds of getting pregnant. As estrogen is a 
vital hormone in fertility, too little body fat causes insufficient production of estrogen 
and disruption of the menstrual cycle. Both under and overweight women have 
irregular cycles in which ovulation does not occur or in inadequate rate. Proper 
nutrition in early part of life is a major factor for later fertility. Dr Barbieri of Harvard 
Medical School has noted that cases of anovulation are quite frequent in women with 
a BMI (BODY MASS INDEX) over 27 kg/m2.  
CHEMOTHERAPY [118]: 
  Therapuetic / stimulating drugs poses a high risk for infertility. Female 
infertility by chemotherapy may be secondary to premature ovarian failure by loss 
of primordial follicles.                        
HYPOTHYROIDISM 
Hypothyroidism – a Greek word. Hypo-refers to “under” Thyroid refers to 
“Thyroid gland”. It is also called as “Hypothyreosis”. Hypothyroidism is one of the 
most common endocrine disorder seen among young women. It is defined as 
deficiency of thyroid hormones secretion & action that produces a variety of clinical 
signs & symptoms of hypometabolism [119,120]. In children, the hypofunctioning gland 
leads to under development of intellect and physical growth called “Cretinism”. 
Hypothyroidism is more common in females than males. 
Thyroid gland dysfunction (hypo-function) causes a variety of symptoms 
involving the entire body resulting in mental and physical sluggishness. The features 
may be due to decreased hormone synthesis or the effects of decreased thyroid 
hormone in target tissue. They have tiredness, cold intolerance, rapid weight gain, 
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menstrual irregularities, either in excess called menorrhagia or Amenorrhoea. They 
may also present with depression, anxiety. Hypothyroidism in early pregnancy 
increases the risk of pre-eclampsia, still birth, cretin child [121,122].   
PREVALENCE: 
TABLE : III 
1. General population[123] 10-11% 
2.  Reproductive age women [124,128] 2-4% 
3. Infertile women [125] 23-37% 
4.  Pregnant women [125] 0.3-0.5% 
5.  Western population [163] 0.3-0.4% 
6.  Subclinical Hypothyroidism [126,127] 3-15% 
              
There are many temporary and permanent causes for reducing thyroid 
hormone secretion and there by leading to hypothyroidism. In most of the conditions 
the problem starts from the gland per se and sometimes from pituitary or 
hypothalamus.  
TYPES OF HYPOTHYROIDISM: 
1. Primary hypothyroidism 
2. Central hypothyroidism 
3. Congenital hypothyroidism 
PRIMARY HYPOTHYROIDISM: [129] 
This is the most common type of hypothyroidism. The defect is within the 
gland, i.e. insufficient production of thyroid hormones. This may be due to nutritional 
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deficiency of Iodine, which is the most common cause for Primary hypothyroidism in 
Iodine deficient area. Autoimmune thyroiditis is the most common cause of 
hypothyroidism worldwide and in non-Iodine deficient area.  
         CAUSES OF PRIMARY HYPOTHYROIDISM: [129] 
 
ENDOGENOUS                              EXOGENOUS 
 
AUTOIMMUNE                                     IODINE DEFICIENCY 
INBORN ERRORS OF            DRUGS 
HORMON DYSGENESIS 
DEVELOPMENTAL                 POST-SURGICAL 
DISORDER OF GLAND 
                                                                     RADIOTHERAPY 
Autoimmune Thyroiditis:  
In autoimmune condition, the body’s immune system is directed towards 
itself. This is the most common cause for primary hypothyroidism worldwide and the 
prevalence is higher in population taking iodine rich diet. Hashimoto thyroiditis, 
atrophic thyroiditis and post partum thyroiditis are the autoimmune thyroid diseases 
of the thyroid gland. In all these forms, the gland is diffusely infiltrated with 
lymphocytes. Both T cells and B cells are deposited in equal amount in the gland. The 
T cells are mistakenly tricked as invaders of its own cells. This stimulates B cells to 
produce antibodies called auto antibodies which destroys the thyroid gland. 
Autoimmune thyroiditis is usually associated with other autoimmune disorders like 
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vitiligo, Sjogren’s syndrome, pernicious anaemia,etc. It occurs in syndrome of 
multiple Autoimmune Endocrinopathies like:  
Type 1: Adrenal failure, hypoparathyroidism 
Type2: Diabetes mellitus (type1), ovarian and adrenal failure. 
Hashimoto Thyroiditis:  
Most common thyroiditis found in United States. It is a genetic disorder 
named after a Japanese doctor who first described the inflammation of thyroid gland. 
It is 20 times more commonly found in female than males. Environmental factors also 
contribute to this condition. Goitre (enlargement of thyroid gland) is usually found in 
these patients. Hashimoto thyroiditis causes permanent damage to the gland and they 
need treatment throughout their life. 
Atrophic Thyroiditis: 
This type of thyroiditis is similar to Hashimoto but without goitre. 
Riedel’s Thyroiditis: 
It is a rare form of thyroiditis in which the thyroid gland is filled with fibrous 
tissues and there by converting the consistency of the gland from soft to stony hard. 
Post-partum Thyroiditis: 
Hypothyroidism can also occur due to antibodies developed toward thyroid 
gland during pregnancy which causes inflammation of the gland after delivery halting 
the thyroid function. 
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Subacute thyroiditis: 
About 10% of hypothyroid cases are due to sub-acute thyroiditis. 
The patient may have silent / painless form or painful / granulomatus form. 
Iodine abnormalities:  
Both deficiency and excess of iodine causes hypothyroidism. 
Drugs: 
Amiodarone contains iodine which interfers with thyroid hormone synthesis, 
Lithium which inhibits thyroid hormone secretion. Drug induced hypothyroidism is 
reversible on discontinuation of the drug.  
CENTRAL HYPOTHYROIDISM: [130] 
Here the defect is at higher level involving pituitary or hypothalamus. Patients 
are symptomatic, with laboratory finding of low freeT4 but TSH not elevated as 
expected may be normal or even below the reference level. It may be secondary 
hypothyroidism, if it involves pituitary gland like surgery or irradiation, congenital 
disorders of pituitary, pituitary apoplexy, sub-arachnoid haemorrhage. Tertiary 
hypothyroidism if it involves the hypothalamus. 
CONGENITAL HYPOTHYROIDISM: [131]  
Thyroid gland dysgenesis, Thyroid dyshormonogenesis, mutation of gene for 
enzyme concerned with thyroid hormones synthesis, maternal antibodies, associated 
with congenital disorder.  
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BIOCHEMICAL CLASSIFICATION OF HYPOTHYROIDISM: 
a) Subclinical Hypothyroidism [132, 133, 134]: 
The prevalence of subclinical hypothyroidism is 3-15% [126,127] and in this 
condition patients have persistently elevated TSH (6-12 wks), but asymptomatic, 
serum free T4 within reference interval. The serum TSH being > 5µU/ mL but <10µU 
/mL. If untreated they may progress to overt hypothyroidism. Every year about 2%-
4% of subclinical hypothyroid patients are progressing to overt hypothyroidism. 
Incidence of SCH increases with age, female gender and greater intake of dietary 
iodine intake. They are found among those who have antibodies and those who don’t 
have it. Subclinical hypothyroidism can cause infertility and miscarriages [135]. They 
are more prone to develop cardio-vascular diseases [136]. There is controversy in 
treating the patient or not who have TSH <10µU/mL.        
b) Overt Hypothyroidism [132, 133]:  
A condition in which serum TSH is elevated more than10µU / mL, with 
symptoms of hypothyroidism. Free T3 and FreeT4 remains elevated only in 
borderline amount. Usually TSH rises only after the fall in T4 / T3. 
TABLE : IV 
TSH T4 INTERPRETATION 
Normal Normal Normal thyroid function 
Elevated Low Overt hypothyroidism 
Normal / Low Low Central hypothyroidism 
Elevated Normal Subclinical hypothyroidism 
  42
THYROID GLAND & ITS HORMONES [137, 138, 139] :        
Thyroid gland is a reddish brown butterfly shaped mass of glandular tissue 
present in front of the neck. It is a paired structure connected by an Isthmus. The 
gland extends from C5-T1 vertebra, and occupies tracheal rings T2, T3, T4. It is the 
first endocrinal gland to develop by about 24th day of Gestation. It originates as a 
proliferation of endodermal cells of median surface of developing pharyngeal pouch 
(1 &2). The precursor of thyroid gland arises as mid line out pouching from foregut to 
form thyroid diverticulum. The thyroid gland descends from the diverticulum 
completely to its place by 7th week. This later gets solidified and then divides into 2 
lobes. From 10th week onwards, fetal thyroid follicles and thyroid hormones are 
demonstrated. Thyroid hormone shows a trend in serum throughout the life. They rise 
from in utero till birth, within hours of birth they reach a peak (cold stress), by 2nd -3rd 
day it falls . TSH rises gradually as age increases.  
Microscopically Thyroid gland consists of Thyroid follicle/ Acini covered by 
basement membrane, Para follicular cells. Each follicle is spherical shaped structure, 
lined by epithelium. These epithelial cells may be squamus or cuboidal and their 
height determine their activity. Centre of the acini is the lacuna that contains colloid 
composed of Thyroglobulin (Tg). 
THYROID HORMONE SYNTHESIS [121, 140]: 
Iodine (I2) in the diet is converted into Iodide (I-) in the intestinal lumen before 
it gets absorbed. 20%of absorbed iodide enters the circulation and 80% is excreted 
through urine. Iodide by circulation enters the thyroid follicular cells through Na / I- 
symport, Na returns out through Na-K ATPase pump. Iodide, through Pendrin, a 
glycoprotein transporter reaches the lacuna where it is oxidised / organified back to 
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Iodine by Thyroperoxidise (TPO). Thyroperoxidase is code by TPO gene and requires 
iron for its action, glutathione is the cofactor for this enzyme.During this oxidation 
hydrogen peroxide is produced in the apical membrane by Dual Oxidase Enzymes 
(DUOX1 & DUOX2). Mutation in this enzyme leads to hypothyroidism [141]. 
Thyroglobulin in lacuna binds with iodine to form Moniodothyronine (MIT), 
Diiodothyronine(DIT), Triiodothyronine(TIT), Tetraiodothyronine(TIT) or Thyroxine 
(T4). Thyroglobulin with T3/T4 serves as reservoir of thyroid hormone within the 
colloid. 
Thyronine is produced by substitution of 2nd phenol group for phenolic ‘H’ in 
Tyrosine residue of Tg by ether linkage. 4 possible sites of iodine attachment are 3, 5, 
3’& 5’. 3 & 5 are in the inner α ring 3’& 5’ in the outer β ring. 
T4 (thyroxine): 3, 5, 3’ & 5’ Tetra iodothyronine. 
T3:  3, 5, 3’ Tri iodothyronine. (80% formed by extra thyroidal conversion of 
T4-T3)           
rT3: 3, 3’& 5’ reverseTri iodothyronine, an isomer of T3 biologically inactive.  
Thyroglobulin (Tg): [140] 
It is a homodimer of 66KDa containing 134 tyrosine residue among which 
only 25-35 alone are iodinated. It has 2 subunits and has 10% carbohydrates. They are 
synthesised by the ribosomes of rough endoplasmic reticulum in follicular cells. 75% 
of glandular protein is thyroglobulin and a very little amount of Tg is released into 
circulation without iodination. TSH is the principle stimulator of Tg synthesis. 
Normal serum concentration is 3-40 ng/mL. When TSH is within normal range, each 
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gm of tissue produced 1ng/mL of Tg. Thyroglobulin is the marker of thyroid 
cancer. 
Thyroid follicular cells have receptor for TSH, when TSH stimulates the gland 
Tg is taken up by the follicular cells by pinocytosis & forms vesicle. This vesicle 
fuses with primary lysosome and forms secondary lysosome. It digests the Tg and 
releases T3 & T4 into thyroid capillary. MIT, DIT within the cell in deiodinised by 
Dehalogenase (Dhal1& Dhal1b) to free iodine and recycled back to new hormone 
synthesis. There are 3 homodimeric deiodinase (selenium dependent) for the 
peripheral metabolism of Thyroxine (T4). 
D1 - Outer & Inner ring deiodinase. 
D2 - Outer ring deiodinase. 
D3 - Inner ring deiodinase. 
About 80% of T3 comes from 5’ deiodination of T4 in the peripheral tissues & 
20% from thyroid gland. T4 to T3 is regulated by D1/ D2/ D3. 40% of T4 is 
converted toT3 & 45% to rT3. Liver, kidney, brain, brown fat, anterior pituitary, 
pineal gland, heart, skeletal muscles are the organs involved in peripheral conversion. 
After sufficient amount of conversion, a small amount of T4 is conjugated with 
sulphate or glucouronic acid and excreted through bile which undergoes entero-
hepatic circulation. 
It is proved that T4/T3 enters the target cell through an organic anion 
transporter called Mono Carboxylate Transporter (MCT-8, 10) [141]. This mechanism 
was previously thought to be a passive diffusion. A special Organic anion transporting 
polypeptide, 1C (ONTP1C) is found in astrocytes. Within the target cells T3 (the 
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active form of thyroid hormone) binds with its receptor (intra-nuclear), act as a 
transcription factor and bind with DNA through Zinc finger motif. 
Thyroxine (T4) [142]: 
This is a tyrosine based hormone with 4 iodine groups at 3, 5, 3’, 5’ secreted 
by the follicular cells of the thyroid gland. The major form of thyroid hormone in 
blood is thyroxine. This hormone, undergoes deiodination in the peripheral tissues 
and thyroid gland and converted to T3, the biologically active form. The half life of 
thyroxine is longer than T3 . The ratio of T4:T3 is roughly 20:1 in the circulation. In 
blood, most of the hormone is protein bound and only a little part is free and is the 
active form freeT4. The major regulator of TSH and TRH release is freeT4. 
Thyroid Hormone Binding Receptor : 
It is a steroid hormone gene super family. Has 15 times more affinity for T3 
than T4. It is of 2 types α and β. α has 3 subunits, β also has 3 subunits. α 1 is 
expressed throughout the body. Maximum TR is in anterior pituitary & adipose tissue 
which are mostly occupied by T3. T4/T3 binds with its receptor and regulates gene 
expression. They have ubiquitous effect in growth and development in all age 
regulates calorigenesis, BMR throughout the life. It also stimulates blood vessel. 
MOLECULAR LEVEL ACTION OF THYROXINE[144]: 
1) Increases O2 consumption within tissues. 
2) Enhances mitochondrial metabolism. 
3) Increases sensitivity of catecholamine to heart tissue & rises heart rate and 
contractility. 
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4) Stimulates protein synthesis & carbohydrate metabolism. 
5) Increases the synthesis & degradation of cholesterol and Triglycerides. 
6) Increases vitamin requirement. 
7) Regulates calcium & phosphate metabolism. 
PHYSIOLOGICAL ROLE OF THYROXIN: 
 Metabolic rate: Increases the oxygen consumption of the cell byincreasing 
2,3 BisPhosphoGlycerate (2,3BPG). T3 binds with its Receptor (intranuclear) 
and this complex T-R binds with DNA through Zinc finger and increases the 
transcription of enzymes in the metabolic pathway. 
 Carbohydrate: Increase intestinal absorption, Protein: Increase protein 
catabolism, Lipid: Decreases Cholesterol in blood byincreasing LDL-Receptor 
in liver. 
 Colorigenic action: Mobilizes fat from adipose tissue and increases the NaK-
ATPase activity.  
 Milksecretion: stimulated. 
 CNS: Increases Reticular activating system. 
 Skeletal muscle: Weakness (protein metabolism). 
 Reproduction: Normal ovulation by menstruation and Fertility. 
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In Circulation [140, 151]: 
T3 & T4 are mostly bound with protein, and the unbound form (0.1%) is 
biologically active. So, only free Thyroid hormone correlates with the clinical 
condition of the patients. The concentration of free T4 is 10 times higher than free T3 
in blood. T3 is ~ 15 times more active than T4. This narrows down the effectiveness 
between the two hormones. Free T4 is the major regulator of TSH secretion.  
TABLE : V 
 THYROID BINDING  
PROTEIN (TBP) 
 
 
THYROID 
BINDING 
GLOBULIN 
(TBG) 
TRANSTHYRETIN 
(TTR) 
 
 
ALBUMIN 
Concentration  4-4.5 mg/dL 10-20 mg/dL  3.5-5g/dL 
Affinity for T4  High Modest  Low 
T4 capacity 
(mcg/dL) 
 
 
22 120  1000 
T4 distribution  67% 20%  13% 
T3 distribution  53% 1%  46% 
 
Albumin, Pre-albumin (TBPA), Transthyretin, Thyroid Binding Globulin 
(TBG) are the proteins involved in binding with T4 & T3. The capacity of Albumin 
for binding with Thyroid hormone is high when compared to TBG, but the affinity for 
Thyroid hormone to bind with TBG is higher than Albumin. Totally, TBG binds more 
T4 than albumin. Protein bound T4=99.98% and protein bounded T3 is 99.80%. i.e 
0.02% of T4 is free and 0.2% of T3 is free in circulation [142]. The euthyroid status is 
maintained even when the TBG is elevated or decreased. Alteration in serum TBG 
profoundly affects total T3/T4 without affecting free hormone level. 
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REGULATON OF THYROID HORMONE SECRETION: 
Hypothalamo - Pituitary - Thyroid gland axis has a negative feedback system 
in regulating thyroid hormone. The major feedback centre is Anterior Pituitary 
(thyrotrophs) and not the hypothalamus. 
Thyrotropin Releasing Hormone (TRH): 
It is a tri-peptide (Proglutamate-Histidyl-Prolinamide) hormone produced by 
paraventricular nuclei of hypothalamus. TRH-Receptor (TRH-R) is a G protein 
coupled receptor in anterior pituitary thyrotroph cells. When TRH binds with its 
receptor, it stimulates the release of TSH from pituitary and also helps for its 
glycosylation. It modifies the sensitivity of thyrotrophs to negative feedback. When 
TRH is high, the sensitivity is decreased and when it is low, the sensitivity of 
thyrotrophs to negative feedback is increased. High TRH reduces the TR in 
thyrotrophs, so less sensitivity to negative feedback which stimulates TSH release in 
excess that is what happens in hypothyroidism. 
TRH+R 
TRIGGERS Ca++INFLUX 
INCREASED INTRA CELLULAR Ca++ 
 
PHOSPHOTIDYL INOSITOL CASCADE              RELEASE OF 
                           PROLACTIN 
TSH RELEASE & GLYCOSYLATION 
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Thyroid Stimulating Hormone [140]:        
The primary regulator of Thyroid hormones is Thyroid Stimulating Hormone 
(TSH), also called as Thyrotropin. It is a 30KDa, heterodimeric glycoprotein having α 
& β subunit. It is secreted by thyrotroph cells of anterior pituitary. The α subunit is 
similar to α subunits of LH, FSH, hCG and has 2 oligosaccharides. The β subunit has 
10 oligosaccharides & specific for TSH & its activities. Active form is glycosylated 
TSH, Non glycosylated form loss potency but retains immune reactivity. Free T4 & 
TSH has inverse relationship that 50% fall in T4 rises TSH by 100 fold. TSH 
secretion is lowest in the late afternoon and highest around hours of sleep. 
Elevated TSH indicates that the gland is not functioning to produce adequate 
Thyroxine. The receptor for TSH is in thyroid follicular epithelial cells. TSH 
Receptor (TR) is a glycoprotein having 743 amino acids. Its molecular weight is 84.5 
KDa and is a G protein coupled receptor. It acquires 2 mode of confirmation, ON 
(Receptor with TSH) and OFF (Receptor without TSH). 
  TSH+Receptor  
PHOSPHOTIDYL INOSITOL PHOSPHATE 
    DAG             IP3 
    PL-C 
INTRA CELLULAR Ca++ 
 
     SYNTHESIS OF Tg     H2O2 SYNTHESIS      Na / I SYMPORT (I- INFLUX)                                
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Only free T4/ freeT3 have feedback regulation and not the protein bound 
form. TSH in turn is regulated by the higher centre thyroid Releasing Hormone (TRH) 
produced by Hypothalamus.  
Reference Interval: [148, 148, 150] 
National Academy of Clinical Biochemistry (NACB) reference level for adult 
is 0.3-3µIU/mL. In United Kingdom, the reference range suggested is 0.4-4.5µIU/mL.  
TSH:   21wk-20yrs: 0.7-6.4 µU/mL, 20-54yrs: 0.4-4.2 µU/mL 
Free T4: 2wk-20yrs: 0.8-2.0 ng/dL, 21-87yrs: 0.8-2.7ng/dL. 
The lower limit of TSH for diagnosing hypothyroidism is not exactly 
determined so far. It has ethnic variation, age variation. According to American 
Thyroid Association (ATA) – 2012 recommendation, serum thyrotropin (TSH) is a 
single and best test for screening primary hypothyroidism in adults for outpatient 
situations. Treating the patients having TSH level in subclinical states (<10µU/mL) is 
tailored according to the patients [149]. Worldwide accepted parameter for screening of 
neonatal hypothyroidism is TSH [147]. 
DYSFUNCTION OF THYROID HORMONE IN MENSTRUATION & 
FERTILITY [152-156]:  
  Thyroid hormones secretion is essential for growth & development of 
reproductive organs. It plays a vital role in maintaining fertility. The impact of 
hypothyroidism in menstruation has been reported from 1950s. Hypothyroidism in 
reproductive age group women cause anovulation or Luteal phase defect, which in 
turn causes menstrual cycle to occur less frequently (oligomenorrhoea) or even to stop 
(amenorrhoea). Rarely do they also result in premature ovarian failure. Animal 
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research has shown collagen deposition within the ovarian intracellular matrix [161]. In 
human hypothyroidism causes mucopolysaccharides (hyaluronic acid& chondroitin 
sulphate) deposition in various organs including ovaries and this increases the ovarian 
volume. Finally, results in dysfunctioning of ovary. Menstruation tends to be 
increased in hypothyroidism and decreased in hyperthyroidism but very often they 
present with oligo/amenorrhoea. Hypothyroidism induced oligo / amenorrhoea is 
either directly by increasing androgen or through another hormone Prolactin, a 
hormone for lactation usually after delivery.  
MECHANISM OF ANOVULATION IN HYPOTHYROIDISM [157]:     
There exists a common regulator at the level of Hypothalamo-Hypophysial 
axis for the secretion of Prolactin and Thyroid Stimulating Hormone. When Thyroxin 
level decreases in blood, it triggers Thyroid Releasing Hormone (TRH) from 
Hypothalamus, which not only stimulates the Thyroid Stimulating  Hormone (TSH), 
It also stimulates prolactin release from anterior pituitary leading to 
Hyperprolactinemia. When Prolactin is increased, the body considers as if in 
lactation and birth control status and causes anovulation. In hypothyroidism the 
combined effect of hyperprolactinemia and hyperandrogenism leads to chronic 
anovulation, and infertility. 
MECHANISM OF HYPERANDROGENISM IN HYPOTHYROIDISM: [158] 
At the Hepatic level, Thyroid hormone influences the synthesis of Sex 
Hormone Binding Globulin (SHBG). Hyperthyroidism stimulates protein (SHBG) 
synthesis but Hypothyroidism inhibits SHBG synthesis. SHBG has high affinity 
toward sex hormones (Testosterone, Estrogen). So,reduced SHBG increases the free 
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androgen (Hyperandrogenism) i.e. free Testosterone, the biologically active form 
and the cause for all clinical features. 
Ghosh S et al, interventional study conducted by Institute of Chemical 
Biology, Reproductive Biology Research division, Calcutta proved the hypothesis - 
hypothyroidism causes elevation of free Testosterone by reducing SHBG, there by 
producing multiple cysts in ovary due to hyperandrogenism. Sergei Avdiushko study 
in Oct 2012, have also shown that treating hypothyroidism in such patients have 
reduced their ovarian volume and the cysts have disappeared. So, infertile female with 
overt or subclinical hypothyroidism should not be ignored. Polycystic ovarian 
syndrome together with hypothyroidism either overt or subclinical have become 
fertile after correcting hypothyroid alone and this shows that reducing the serum TSH 
will reduce free testosterone, estrogen, ovarian volume, bring back the fertility. A 
woman diagnosed as PCOS should be evaluated for hypothyroidism without fail. The 
very first test to evaluate thyroid function status is estimating TSH level for women 
attending infertility / Gynaecology clinic. TSH was alone used for screening 
hypothyroidism in by Linclon et al.[142] and setting the upper physiological limit for 
TSH is still under investigation. This occult hypothyroidism which is a treatable cause 
for menstrual disorder and infertility if detected early could be treated. By an easy and 
simple tests like serum TSH the burden of the disease could be assessed. All the 
above factors and concepts made us to conduct this study with our population.  
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EVALUATION OF THYROID FUNCTION TEST 
 
                                                       TSH 
 
 
 
 
 
       Increased                        Normal                          Decreased 
 
 
 
 
         Free T4                         No Further Test                    Free T4 
 
 
 
 
  : Thyroid Hormone Resistance             : Pri. Hyperthyroidism 
 
 N: Subclinical Hypothyroidism             N: Do Serum T3 
 
 : : Pri. Hypothyroidism                       :Central Hypothyroidism 
  
Evaluation of Thyroid function status begins with detailed history, physical 
examination, and biochemical investigation. In biochemical investigation, the very 
first test is estimation of serum TSH. If it is within reference limit, then this rules out 
thyroid disorder and they need not be subjected to further evaluation of thyroid 
function. If TSH elevated, then the next step is to estimate the T4, ideally free T4. The 
cause for hypothyroidism may be gland dysfunction or peripheral tissue uptake 
disorder (resistance) where thyroxine is in adequate amount without its physiological 
role. The overall effect is hypometabolism and other features of hypothyroidism. This 
stimulates the anterior pituitary to secrete TSH so, whatever the etiology may be the 
effect of reduced active thyroid hormone is elevated TSH.Thus, TSH is sufficient for 
screening hypothyroidism and we have followed this protocol in screening for 
hypothyroidism in our study population. 
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There are different assay for estimating TSH. Shifting towards more sensitive 
methods 2 decades ago prompted a change in strategy for laboratory investigation of 
thyroid dysfunction. Depending upon the analytical sensitivity, the assays are given 
generation numbers. First generation, second, third, fourth generations are available. 
Generations and their analytical sensitivity:  
1st generation: 1mU/L or 1(µU/mL) 
2nd generation: 0.1 mU/L 
3rd generation: 0.01 mU/L 
4th generation: 0.001 mU/L 
Using highly analytical sensitive technique is gives the better resolution and 
perfect assessment. 
             
Hypothalmus (GnRH)
FSH LH
Prolactin
TSH
Reduced
SHBG
Free Androgen
(Testosterone)
Acne
Hirsutism
Anovulation
Infertility
Hypothyroidism
Inhibin
Anterior Prituitory
Ovary
Anterior Pituitary
Hypothalmus (TRH)
Liver
(-
)
(-
) (+)
(+)
HYPOTHESIS
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AIM AND OBJECTIVE: 
1) To assess the Thyroid function status using serum TSH and estimate the 
prevalence of hypothyroidism in newly diagnosed PolyCystic Ovarian 
Syndrome patients.  
2) To compare certain hormones and parameters between euthyroid and 
hypothyroid patients having Polycystic ovarian Syndrome. 
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MATERIALS AND METHODOLOGY: 
In our study, we selected 73 post pubertal women who came with complaints 
of menstrual irregularities for a period of three months and /or infertility  from 
Institute of Obstetrics & Gynaecology and medical Endocrinology clinic attached to 
Madras Medical College. With the ultrasound evidence of polycystic ovaries we 
proceeded the study. This study was approved by Institutional Ethic Committee. 
Study design:  A cross sectional, observation study. 
Inclusion criteria : 
1.  Women aged between 15-35 yrs with menstrual irregularities or Infertility. 
 2.  PCOS confirmation based on revised Rotterdam criteria 2003: (2 / 3 criteria 
should be satisfied) 
1. History of oligomenorrhoea (cycle lasting more than 35 days) or long 
cycles /Amenorrhoea (no cycles in the past 6 months).                     
2.  Clinical and / or Biochemical features of hyperandrogenism. 
3.   Ultra sonogram finding : Multiple cysts (> 12 in number of 1-2mm) 
either one or both ovaries. 
Other cause of hyperandrogenism like Congenital adrenal hyperplasia, Virilising 
tumor, Prolactinoma, Cushing syndrome should be ruled out. 
Clinical hyperandrogensm is defined as to have acne and / or hirsutism and / or 
androgenic  
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pattern of alopecia. Biochemical hyperandrogenism was defined as elevated 
testosterone .  
Exclusion criteria: 
1. Patients on treatment for Hypothyroidism, Oral contraceptives, 
Anticonvulsants, Metformin.  
2. Other conditions mimicking PCOS were ruled out by detailed history and 
complete physical examination.                              
PHYSICAL EXAMINATION: 
1) Height (cms): Measured with Inch tape. 
2) Weight (kg): Measured in weighing machine. 
3) Waist circumference:  According to WHO, the waist circumference should be 
measured at the midpoint between the lower margin of the last palpable rib and 
top of the iliac crest using a stretch resistant tape [159]. This point will be roughly 
1 inch above the umbilicus.   
 (Ethnic specific value for Asian Indian Female : 80 cm) [160] 
4) Hip circumference: According to WHO, the Hip circumference should be 
measured around the widest portion of the buttock, with inch tape parallel to the 
floor. 
BIOCHEMICAL INVESTIGATIONS: 
1) Fasting Blood Glucose. 
2)  2hrs post glucose. 
3) Fasting (TSH) Thyroid Stimulating Hormone. 
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4) Fasting Insulin. 
5) Total Testosterone. 
CALCULATED PARAMETERS: 
1) HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE ( 
HOMA-IR):                        
A valid method of assessing Insulin Resistance is HOMA-IR. 
Homeostatic Assessment Model of Insulin Resistance (HOMA-IR) 
              = Fasting plasma Insulin (µU/mL) * Fasting plasma glucose (mmol  
                                                               22.5 
2) BODY MASS INDEX (BMI) / QUETLET INDEX: 
It is defined as the individual’s body mass divided by the square of their height, with 
the value universally being given in units of Kg/M2                                               
                                     BMI    =  Weight in Kg 
                                                 Height in Metre2  
WHO BMI CLASSIFICATION [162]   
                                
BMI RANGE CATEGORY 
Very severely underweight <15 
Severely underweight 15-16 
Underweight 16-18.5 
Normal 18.5-25 
Overweight 25-30 
Obese class 1 
(moderately obese) 
30-35 
Obese class 2 
(severely obese) 
35-40 
Obese class 3 
(very severely obese) 
>40 
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3) WAIST/ HIP RATIO: It is the ratio of Waist circumference to Hip 
circumference.It is an Index of central obesity.  
  
Normal: <0.85.                                              
WHO STEPS: states that abdominal obesity is defined as a waist/Hip ratio >0.9 for 
male and  >0.85 for female, or Body Mass Index >30. [161] 
Patient preparation:  
Patient was advised to come in 8-10 hrs fasting. They were adviced to take 
their dinner by 8 PM on the previous day, then no food should (carbohydrate diet) be 
taken. Next day morning tea / coffee / any carbohydrate drink should avoided. Patient 
was to sit in a chair calmly and with stretched forearm. Blood was drawn by 7-8AM 
under aseptic precaution.   Fasting sample was collected for Glucose, Insulin, 
Testosterone, TSH, then 75gm of glucose dissolved in 300ml of water was given to 
the patients and allowed to take for a period of 5 min. Post glucose sugar sample was 
taken 2 hrs after drinking glucose.In the mean time patients were instructed not to do 
exercise or walking for long distance. 
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BLOOD SAMPLING: 
Fasting Glucose: 
5mL of blood was drawn from cubital vein. The collected blood was 
transferred in to a plain test tube and kept aside without any disturbance. After the clot 
was formed completely (15-20 min) it was centrifuged for 15-20 min at 2000 rpm and 
the clear serum was separated and aliquoted for Glucose and hormone assay. Serum 
for hormone assay was stored in deep freezer at -200c until it was processed.  
2 hrs Post Glucose: 
Two hours after Glucose load, 1mL blood was drawn from the cubital vein, 
and then transferred to a plain clean test tube. The blood collected was kept 
undisturbed for few minutes. After separation of the clot, it was subjected to 
centrifugation for 15 min at 2000 rpm. Clear serum was taken for estimating Glucose 
level.  
FASTING BLOOD GLUCOSE ESTIMATION: 
 METHOD:  Trinder’s GLUCOSE OXIDASE- PEROXIDASE-using ERBA Glucose 
reagent. 
PRINCIPLE : 
Glucose present in the sample is oxidised by (GOD) Glucose Oxidase in the 
reagent to Gluconic acid and hydrogen peroxide. This hydrogen peroxide produced is 
cleaved in to water and nasent oxygen by peroxidase in the reagent. The nasent 
oxygen binds with the substrate 4-Amino Anti pyrin  (4-AAP) and phenol. After the 
Incubation period it gives pink colored complex Quinoneimine dye. The intensity of 
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the colour formed is directly propotional to the concentration of  glucose present in 
the sample. The color formed is measured at 520 nm by Spectrophotometer.  
                                                          Glucose-oxidase 
                          Glucose+ O2 + H2O                            Gluconic acid + H2O2 
                                                              
         Peroxidase 
                           H2O2 + Phenol + 4-AAP                         Quinoneimine dye + H2O
                                    (Pink Color) 
ASSAY PARAMETERS: 
Mode: End point 
Wavelength: 505nm 
Sample volume (µL): 10 
Reagent volume (µL): 1000 
Reaction time: 5 min 
Linearity: 500 mg/dL 
Standard concentration: 100 mg/dL 
Blank absorption limit: 0.2 
PROCEDURE: 
1000µL of GOD-POD reagent (ERBA) was taken in a dry clean test tube, to that 
10µL of the sample was added and mixed well. It was kept under incubation for  
10 min. After 10 min, reading was taken in a spectrophotometer at 510nm. The 
concentration is directly propotional to the intensity of the color formed. 
Reference Interval: 
Fasting Blood Glucose = 70-110 mg/dL 
            Post Glucose = <140 mg/dL. 
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CHEMILUMINESCENCE[164,165] 
Principle: 
A chemiluminescence reaction is any chemical reaction in which one of the 
products of the reaction is light. The enzyme peroxidise can react with molecules such 
as luminal (5-amino-2,3-dihydro-1,4-phthalazinedione) to yield light as part of the 
reaction product. The luminol reaction results in photon emission in the range of 400-
450nm. The low photon yield is enhanced by using enhancers (luziferin, 6-
hydroxybenzothiazole), the reaction can be followed for many minutes with several 
thousand times increase in photon output. 
The peroxidase is often part of an enzyme labelled immunoassay system in 
which peroxidase is the label. The reaction can be measured by very sensitive 
photomultiplier tube.  
The major advantage of the technique is : High sensitivity. 
The major disadvantage is : It needs separation step to remove matrices. 
Other dye system that produces quantitative chemiluminescence reaction use 
aromatic acridinium esters and the dioxetanes. The acridinium esters are oxidised 
most often by hydrogen peroxide to yield light, whereas the dioxetanes are made into 
stable phosphate ester derivatives that, when hydrolysed, become spontaneously 
degraded, yielding light as one of the product. A light beam at 680nm is used to create 
singlet oxygen atom O2*. These very reactive singlet oxygen atoms react with a dye 
to yield light, which in turn is transferred to a flurophore dye that emits fluorescence 
light. 
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Bio-luminescence: The naturally occurring chemiluminescence. 
Electro-chemiluminescence: This is based on the formation of an exited state 
chemical intermediate that returns to the ground state by emitting a photon. 
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INSULIN ASSAY: 
METHOD: AUTOMATED IMMUNOASSAY TECHNIQUE- 
CHEMILUMINESCENCE using Siemens  ADVIA Centaur XP system. 
PRINCIPLE:                 
Insulin assay, is a two site sandwich immune assay using direct 
chemiluminescent technology, which uses constant amount of two antibodies. The 
first antibody, in the LITE reagent, is a monoclonal Mouse anti-Insulin antibody 
labelled with acridinium ester. The second antibody, in the solid phase, is a 
monoclonal Mouse anti Insulin antibody, which is covalently bounded to 
paramagnetic particle.  
PROCEDURE:                                    
Before estimation, the sample was completely thawed, mixed then placed in 
the rack and it was ensured of no fibrin or any other particulate matters or bubbles in 
the sample.  
1) The sample tube was labelled properly with the sample number and 
placed in the sample rack in queue provided in the system. 
2) The reagent is also kept in the reagent tray/disc. The position for the 
reagent was fed into the system. 
 
3) 25µL of the sample was dispensed into a cuvette. 
                   
4) 50µL of Lite reagent was added into the cuvette and incubated for 5 
min at 370c  
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5) Now dispense 250µL of solid phase and incubate for 2.5 min at 370c. 
 
6) After the incubation time, the magnetic particles were washed with 
reagent water. 
7) Next, 300µL of each acid and base reagent were dispensed to initiate 
chemiluminescent reaction. 
The chemical light reaction was measured by the Photo Multiplier Tube 
(PMT). A direct relationship exists between the Insulin present in the sample detected 
by the system and the amount of Relative Light Units (RLUs) 
REAGENTS IN ADVIA CENTAUR: 
1. LITE REAGENT: 
5mL / reagent pack: monoclonal mouse anti insulin antibody (0.24µg/mL) 
labelled with Acridinium ester in buffered saline with bovine serum albumin, Sodium 
azide (<0.1%), and preservatives. 
2. SOLID PHASE: 
25mL/ reagent pack: monoclonal mouse anti Insulin antibody (6.0µg/mL) 
covalently coupled with paramagnetis particles in buffered saline with bovine serum 
albumin, sodium azide (<0.1%), and preservatives. 
3. INSULIN DILUENT: 
10.0mL / reagent pack: buffered saline with casein, potassium  thiocyanate 
(3.89%), sodium azide (<0.1%), and preservatives. 
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CALIBRATION:  Two point calibration interval Using IRI calibrator, two 
point calibrations was done using a Calibrator Assigned Value card.  
QUALITY CONTROL: 
Bio-Rad Immnuoassay plus control 1, 2 & 3 were used. 
Each control was reconstituted with 5.0mL of CLRW (Clinical Laboratory 
Reagent Water). 
The reportable range in ADVIA centaur Insulin assay is 1-1500 mU/L. 
Reference Interval : 3.3-22.1 mU/L    
Interferences:  Hemolysis, Lipemia, Jaundice shows <6% changes in results. 
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TOTAL TESTOSTERONE ASSAY: 
METHOD: AUTOMATED IMMUNOASSAY TECHNIQUE – 
CHEMILUMINESCENCE using  seimen’s ADVIA Centaur  XP system. 
PRINCIPLE:   
Competitive Immunoassay using direct Chemiluminesence technology. 
Testosterone in the patient sample competes with Acridinium ester- labelled 
testosterone in the LITE reagent for a limited amount of Polyclonal rabbit anti 
testosterone antibody bounded to monoclonal mouse anti- rabbit antibody, which is 
coupled to paramagnetic particles in the solid phase. The assay uses Testosterone 
releasing agent to release bound testosterone from the endogenous  binding  protein in 
the sample.  
PROCEDURE:        
Samples were loaded in the entry queue and analysed as follows 
1) 15µL of sample and 50µL of Releasing agent were dispensed into a cuvette. 
2) After ensuring that the Probe wash is perfect, now dispense 50µL of LITE 
Reagent and 300µL of solid phase and incubate for 5 minutes at 37C. 
3) It separates, aspirates and washes the cuvette with reagent water. 
4) Dispenses 300µL each of Acid reagent and Base reagent to initiate the 
chemiluminescent reaction. 
5) An inverse relationship exists between the amount of Testosterone present in the 
sample and the amount of Relative Light Units.(RLUs) detected by the system. 
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REAGENTS: 
ADVIA Centaur TSTO Ready pack (Primary reagent pack). 
1) LITE REAGENT:  2.5mL/ reagent pack has acridinium ester-labelled 
testosterone (~ 3.2 ng/mL) in buffered saline with preservatives.  
(maintained at 2-80C) 
2) SOLID PHASE: 15mL/ reagent pack has polyclonal rabbit anti 
testosterone antibody (~0.03µg/mL) bound to monoclonal mouse anti- 
rabbit antibody (0.53µg/mL) covalently coupled to paramagnetic  
particles in buffered saline with sodium azide (0.1%) and preservatives. 
Stored at 2-8C. 
 
3) PROBE WASH: 10mL/ reagent pack has buffered saline with sodium 
azide (0.1%) and preservatives. 
ADVIA Centuar TSTO Ready Ancillary pack (Releasing agent pack).                       
It has 5.0mL/ reagent pack has steroid releasing agent (~0.1µg/mL) in buffered saline 
with Sodium azide (0.1%) and preservatives. It is also stored in 2-80C.  
ADVIA Centuar : Ready pack Ancillary reagent pack: 
Multi-Diluent 3 has 5.0mL/ reagent pack. It has human plasma with Sodium azide 
(0.1%) stored at 2-80C.  
CALIBRATION:   Two point calibration  
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QUALITY CONTROL:   
Two levels of Quality control materials were used and treated along with all 
Sample. Bayer Health Care material were used. Expiry date was checked. 
DILUTION : For serum having high value of Testosterone (>1500ng/dL) automatic 
dilution was programmed in the system using Multi-Diluent 3. Dilution factor 5 is 
applied. 
Reference Interval:  
Young Female: 14-76 ng/dL. 
Interference: Hemolysed, Lipemia, Jaundice sample showed interference in the 
assay. 
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THYROID STIMULATING HORMONE (TSH) / THYROTROPIN ASSAY: 
METHOD: AUTOMATED IMMUNOASSAY TECHNIQUE – 
CHEMILUMINESCENCE using Siemens ADVIA centaur XP system.        
PRINCIPLE: 
A 3rd generation TSH assay is a Non-Competitive two site Sandwich 
immunoassay using direct chemiluminometric technology.  It uses constant amount of 
two antibodies. The first antibody, in the LITE reagent is a monoclonal mouse anti-
TSH antibody labelled with acridinium Ester. The second antibody, in the solid phase, 
is a polyclonal sheep anti-TSH antibody which is covalently coupled to paramagnetic 
particles. These two antibodies holds the analyte of interest tightly. Seperation of 
magnetic field and washing removes materials unbound to the solid phase. 
Chemiluminescent substrate added to the reaction cuvette generates photons (light), 
light generated by the reaction is measured by the Luminometer. The photon 
production is propotional to the amount of conjugate bound to solid support. A direct 
relationship exists between the amount of TSH present in the patient sample and the 
amount of relative light units (RLUs) detected by the system. 
PROCEDURE: 
Serum was thawed completely and mixed well before keeping in the sample tray. 
Fibrin, particulate matter and bubbles were checked before analysis.                           
1) The sample tube was labelled properly with the sample number and 
placed in the sample rack. 
2) The reagent is also kept in the reagent tray/disc. The position for the 
reagent in  fed in the system. 
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3) 200µL of the sample was dispensed into a cuvette.                   
4) 50µL of LITE reagent and 225µL of solid phase were dispensed into 
the cuvette and incubated for 7.5 min at 37 c. 
5) After incubation, it separates, aspirates and washes the cuvette with  
reagent water. 
6) Then, it dispenses 300µL each of acid and base reagent to initiate 
chemiluminescent reaction. 
7) A direct relationship exists between the amount of human TSH present 
in the sample and the amount of Relative Light Units (RLUs) detected 
by the system. 
REAGENTS :               
          TSH Ready packs Primary reagent pack: 
 LITE REAGENT: 
5mL /Reagent pack has monoclonal mouse anti TSH antibody (~333 ng/mL) labeled 
with acridinium ester in phosphate buffered saline with sodium azide (<0.1%) and 
preservatives stored at 2-80C 
SOLID PHASE: 
22.5mL/ Reagent pack has polyclonal sheep anti TSH antibody (~43µg/mL) 
covalently coupled with paramagnetis particles in phosphate buffered saline with 
protein stablizers,  sodium Azide (<0.11%) and preservatives stored at 2-80C.                   
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      Ready pack ancillary reagent pack: 
MULTI-DILUENT 1: 
25 mL / reagent pack has equine serum with sodium azide (0.1%), and preservatives 
stored at 2-8C. Dilution factor 2, 5. Dilution point : ≤ 150µIU/mL. 
CALIBRATION:    Two point calibration was done using a CALIBRATOR  
ASSIGNED VALUE CARD.     
 QUALITY CONTROL: 
Bayer Health care two level quality control samples were run. 
Each control was diluted with 5.0mL of CLRW (Clinical Laboratory Reagent 
Water)                         
Reference Interval:  3.5-5.5µU/mL    
Interferences: Hemolysis, Lipemia, Jaundice shows <6% changes in results. 
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STATISTICAL ANALYSIS 
 Statistical analysis is done by SPSS software version 17. 
 
1. Student t- test & Chi-square test were applied for comparing Age, BMI, WHR, 
FBS, PPBS, Ovarian volume, Testosterone, HOMA-IR between the two 
groups of PCOS patients (with Euthyroid and Hypothyroidism). 
2. Pearson co-efficient correlation was applied for TSH & Testosterone, Total 
Testosterone & WHR. 
 
 
  
S.NO AGE C.CENTRMAIN C/O ASSO C/O MEN. MARRFAM. WAISTHIP W/H HT(CM WT(Kg)BMI NECKUGS OV.V OV.VFBS m PPBS F.IN(mIUTSH(µIU/TESTO(nFBS(mmHOMA-IR
1 25 EGM OLIGO,INFER acne, hirs, 13 1 NO/0 86 107 0.80 140 62 31.63 N/0 B/L PCO 10 6 87 121 13.6 1.97 91.6 4.83 2.92
2 20 EGM OLIGO,INFER 14 1 0 73 90 0.81 150 55 24.44 0 B/L PCO 11 11 86 104 12.6 4.33 26.2 4.78 2.68
3 21 EGM OLIGO,INFER,W ACne, 18 1 0 72 92 0.78 156 55 22.60 Goit1 B/L PCO 11 12 105 105 6.69 1.3 33 5.83 1.73
4 21 EGM OLIGO,WT HIRSUITISM 12 0 YES/1 95 117 0.81 155 63 26.22 1 B/L PCO 11 9 82 108 16 3.1 40 4.56 3.24
5 28 EGM OLIGO, WT ACNE,HIRSUITI 14 1 0 86 115 0.75 162 76 28.96 1 B/L PCO 10 10 96 126 16.6 2.49 43.03 5.33 3.93
6 23 EGM OLIGO, WT ACNE 14 0 1 82 98 0.84 154 50 21.08 0 B/L PCO 9 10 80 114 4.5 1.23 96.5 4.44 0.89
7 34 EGM INFERTILITY HIRSUITISM 14 1 0 85 103 0.83 170 75 25.95 0 B/L PCO 15 11 146 254 11.4 2.45 30 8.11 4.11
8 27 ENDO OLIGO,INFER,W ACNE,HIRSU,W 15 1 1 108 116 0.93 164 81 30.12 0 B/L PCO 9 12 115 123 29.73 2.03 141.7 6.39 8.44
9 28 EGM OLIGO,INFER,W ACNE 14 1 0 95 117 0.81 155 83 34.55 1 B/L PCO 10 9 89 126 23.68 11.2 89 4.94 5.20
10 23 ENDO OLIGO,INFER,W ACNE 12 1 0 92 107 0.86 155 100 41.62 1 B/L PCO 10 11 100 115 6.01 4.1 10.4 5.56 1.48
11 30 EGM OLIGO,INFER,W HIRSUITISM 13 1 0 84 92 0.91 149 59 26.58 0 B/L PCO 11 13 84 138 16 1 84.8 4.67 3.32
12 20 EGM INFERTILITY ACNE 13 0 0 70 84 0.83 162 48 18.29 0 B/L PCO 14 14 76 104 10 3 42 4.22 1.88
13 31 EGM INFERTILITY ACNE 16 1 1 75 83 0.90 156 39 16.03 0 B/L PCO 13 10 86 152 7.4 1 22.8 4.78 1.57
14 22 ENDO OLIGOINFER,WTACNE 13 1 0 96 112 0.86 155 76 31.63 1 B/L PCO 9 9 80 112 23.6 10.3 40.1 4.44 4.66
15 23 EGM OLIGO ACNE 15 1 1 80 98 0.82 159 55 21.76 0 B/L PCO 12 13 96 115 14.9 4.8 44.5 5.33 3.53
16 33 EGM OLIGO, INFER 15 1 0 92 114 0.81 160 76 29.69 0 B/L PCO 13 13 90 178 247 1.13 49.5 5.00 54.89
17 22 ENDO AMENO,WT,INFEHIRSUITISM 14 0 0 94 99 0.95 170 73 25.26 0 B/L PCO 8 9 100 112 22 0.46 76.8 5.56 5.43
18 18 ENDO AMENO,WT HIRSUITISM 14 0 1 85 91 0.93 155 65 27.06 0 B/L PCO 14 9 72 89 6.1 1.3 17 4.00 1.08
19 30 EGM AMENO 14 1 0 76 89 0.85 148 53 24.20 0 B/L PCO 13 19 97 140 6.9 2.4 48.3 5.39 1.65
20 23 ENDO OLIGO,WT ACNE 13 0 1 72 100 0.72 162 70 26.67 0 B/L PCO 8 11 79 115 10.5 0.46 93 4.39 2.05
21 28 ENDO AMENO,WT 13 0 0 77 98 0.79 150 56 24.89 0 U/L PCO 12 9 72 126 9.26 4.2 56.3 4.00 1.65
22 32 EGM OLIGO, 13 1 0 89 109 0.82 162 64 24.39 0 B/L PCO 10 12 108 163 31.4 2.32 26 6.00 8.37
23 28 EGM INFERTILITY, WTHIRSUITISM 14 0 0 82 109 0.75 161 70 27.01 1 B/L PCO 12 11 107 128 11.1 8.29 17.1 5.94 2.93
24 30 EGM OLIGO, 16 1 0 78 88 0.89 150 50 22.22 0 B/L PCO 11 13 68 143 18.7 1.34 67.7 3.78 3.14
25 28 EGM OLIGO,WT 14 1 0 101 116 0.87 156 78 32.05 0 B/L PCO 12 14 79 129 10.5 1.95 43.1 4.39 2.05
26 23 EGM INFERT, WT ACNE 16 1 0 80 102 0.78 148 62 28.31 0 B/L PCO 10 11 53 116 10 1.27 38.9 2.94 1.31
27 24 ENDO OLIGO,AMENO,WHIRSUITISM 12 1 0 110 122 0.90 155 85 35.38 0 U/L PCO 30 16 74 119 7.6 2.12 67.9 4.11 1.39
28 30 ENDO OLIGO,AMENO,WACNE,HIRSUITI 14 1 0 111 129 0.86 153 96 41.01 0 B/L PCO 10 8 78 144 13 3.5 41 4.33 2.50
29 30 EGM OLIGO,INFER,WT 14 1 0 94 105 0.90 150 64 28.44 0 U/L PCO 9 14 66 155 28 3.5 10.9 3.67 4.56
30 33 ENDO ,AMENO,INFER,WHIRSUITISM 14 1 0 85 101 0.84 160 65 25.39 1 B/L PCO 13 13 72 318 30 8.6 11 4.00 5.33
31 17 EGM OLIGO,WT HIRSUITISM 12 0 0 84 91 0.92 156 55 22.60 0 U/L PCO 13 14 86 74 11.8 1.7 51.7 4.78 2.51
32 24 EGM OLIGO,INFER,W HIRSUITISM 15 1 0 115 125 0.92 150 90 40.00 1 B/L PCO 11 11 69 120 16.8 4.88 59.9 3.83 2.86
33 29 EGM OLIGO,INFER ACNE 12 1 0 97 113 0.86 150 65 28.89 0 B/L PCO 10 10 92 133 24 1.9 90 5.11 5.45
34 24 EGM OLIGO,AMENO,WRECUR-PREG L 12 1 0 100 103 0.97 161 75 28.93 0 B/L PCO 11 17 92 120 36 3.4 98.8 5.11 8.18
35 17 ENDO OLIGO,WT ACNE,HIRUITIS 11 0 0 71 90 0.79 161 57 21.99 0 B/L PCO 11 12 70 88 28 2.72 84.1 3.89 4.84
36 23 EGM OLIGO,AMENO,WACNE 13 1 0 86 106 0.81 148 70 31.96 0 B/L PCO 10 11 96 116 52 25.4 69.4 5.33 12.33
37 20 EGM OLIGO,AMENO,I ACNE 12 1 0 81 94 0.86 140 57 29.08 1 B/L PCO 16 15 72 104 30.4 5.5 77.5 4.00 5.40
38 30 EGM OLIGO,INFER ACNE 11 1 0 78 93 0.84 150 54 24.00 0 B/L PCO 12 9 80 146 26.8 7.8 65.9 4.44 5.29
39 30 EGM OLIGO,INFER,WT 18 1 0 88 95 0.93 150 50 22.22 0 B/L PCO 12 10 132 176 30 2.36 88.1 7.33 9.78
40 22 EGM OLIGO,WT HIRSUITISM 13 1 1 79 101 0.78 152 64 27.70 0 B/L PCO 9 10 84 112 20 6.6 22 4.67 4.15
41 27 EGM OLIGO,WT ACNE,GALAC 13 1 0 88 98 0.90 140 56 28.57 1 U/L PCO 11 11 88 124 22 2.55 96 4.89 4.78
42 32 EGM WT HIRSUITISM 12 1 0 105 123 0.85 159 95 37.58 0 B/L PCO 15 10 81 172 35 6.9 12.7 4.50 7.00
43 26 ENDO OLIGO,AMENO,INFER 12 1 1 82 96 0.85 148 57 26.02 0 B/L PCO 10 9 72 122 24 28.5 90 4.00 4.27
44 19 EGM AMENO,WT ACNE,HIRSUITI 14 0 1 91 113 0.81 160 80 31.25 1 B/L PCO 15 16 129 140 11.34 1.31 60 7.17 3.61
45 27 ENDO AMENO,INFER,WT 15 1 0 100 118 0.85 142 75 37.20 0 B/L PCO 12 13 91 124 18.9 3.17 56 5.06 4.25
46 21 EGM OLIGO,WT HIRSUITISM 13 0 0 104 117 0.89 163 85 31.99 0 U/L PCO 11 10 82 111 26.8 1.85 80.6 4.56 5.43
47 23 EGM OLIGO,WT ACNE 13 0 0 100 116 0.86 166 100 36.29 0 B/L PCO 12 14 72 117 12 5.11 88 4.00 2.13
48 22 EGM OLIGO,INFER ACNE 14 1 1 94 108 0.87 148 58 26.48 0 B/L PCO 10 12 105 114 24 4.46 98 5.83 6.22
49 21 ENDO OLIGO ACNE 16 1 0 90 112 0.80 153 58 24.78 0 B/L PCO 12 10 80 112 16 100 83 4.44 3.16
50 19 EGM OLIGO,WT 14 0 1 70 91 0.77 145 51 24.26 1 U/L PCO 13 9 126 134 21 3.49 51.4 7.00 6.53
51 28 EGM OLIGO,WT ACNE 15 0 0 102 146 0.70 148 85 38.81 0 B/L PCO 12 not vi 70 129 18 2.2 21 3.89 3.11
52 26 EGM OLIGO,INFER,WT 13 1 0 99 135 0.73 161 70 27.01 0 B/L PCO 11 cyst 91 122 25 3.73 41.8 5.06 5.62
53 23 EGM INFER HIRSUITISM 14 1 0 94 132 0.71 152 76 32.89 0 B/L PCO 11 10 96 117 20 6.2 61 5.33 4.74
54 27 EGM OLIGO,INFER ACNE 13 1 0 90 130 0.69 155 59 24.56 0 B/L PCO 10 11 146 124 20 1 62.5 8.11 7.21
55 25 EGM OLIGO,INFER,W RECUR-PREG L 14 1 1 76 90 0.84 144 60 28.94 0 B/L PCO 11 9 83 122 13 6.9 71 4.61 2.66
56 22 EGM OLIGO,INFER,W ACNE 14 1 0 97 120 0.81 164 52 19.33 0 B/L PCO 9 11 78 114 34 1.1 22 4.33 6.55
57 28 EGM OLIGO,WT 16 1 0 85 100 0.85 168 68 24.09 0 B/L PCO 10 8 96 130 10.9 4 98.1 5.33 2.58
58 32 EGM OLIGO,INFER,W HIRSUITISM 15 1 0 108 145 0.74 140 69 35.20 0 U/L PCO 12 13 91 175 13.24 1.2 29 5.06 2.97
59 20 EGM OLIGO,AMENO,INFER 13 1 0 66 88 0.75 143 47 22.98 0 B/L PCO 15 13 74 104 7.7 2.7 36.3 4.11 1.41
60 28 EGM OLIGO,INFER,W ACNE 28 1 1 107 147 0.73 162 79 30.10 0 B/L PCO 11 12 87 133 31.6 4 31.9 4.83 6.79
61 17 ENDO OLIGO,WT ACNE,HIR 13 0 0 98 139 0.71 153 98 41.86 0 U/L PCO 10 13 97 89 74.7 5.5 94.3 5.39 17.89
62 18 ENDO AMEN,WT ACNE 13 0 0 93 123 0.76 154 76 32.05 1 B/L PCO 11 13 96 90 8.01 1.17 29 5.33 1.90
63 20 EGM OLIGO,INFER HIRSUITISM 24 1 0 88 121 0.73 162 67 25.53 0 B/L PCO 22 19 86 104 33.8 4 55.7 4.78 7.18
64 30 EGM OLIGO,INFER,W HIRSUITISM 13 1 0 84 92 0.91 149 59 26.58 0 B/L PCO 12 11 84 147 16 1 84.8 4.67 3.32
65 19 EGM INFERTILITY ACNE 13 0 0 70 84 0.83 162 48 18.29 0 B/L PCO 13 10 76 104 10 3 42 4.22 1.88
66 33 EGM INFERTILITY ACNE 16 1 1 75 83 0.90 156 39 16.03 0 B/L PCO 12 14 86 160 7.4 1 22.8 4.78 1.57
67 22 ENDO OLIGOINFER,WTACNE 13 1 0 96 112 0.86 155 76 31.63 1 B/L PCO 10 11 80 114 23.6 10.3 40.1 4.44 4.66
68 23 EGM OLIGO ACNE 15 1 1 80 98 0.82 159 55 21.76 0 B/L PCO 12 15 96 118 14.9 4.8 44.5 5.33 3.53
69 33 EGM OLIGO, INFER 15 1 0 92 114 0.81 160 76 29.69 0 B/L PCO 16 11 90 178 247 1.13 49.5 5.00 54.89
70 21 EGM OLIGO, INFER 15 1 0 78 98 0.80 154 61 25.72 1 B/L PCO 10 8 94 112 17 4.8 38 5.22 3.95
71 22 ENDO AMENO,WT,INFEHIRSUITISM 14 0 0 94 99 0.95 170 73 25.26 0 B/L PCO 12 14 100 114 22 0.46 76 5.56 5.43
72 18 ENDO AMENO,WT HIRSUITISM 14 0 1 85 91 0.93 155 65 27.06 0 B/L PCO 15 10 72 98 6.1 1.3 71 4.00 1.08
73 21 EGM OLIGO, INFER 15 1 0 78 98 0.80 154 61 25.72 1 B/L PCO 12 14 94 112 17 4.8 38.9 5.22 3.95
MEAN 24.8 88.88 107.8 0.83 154.6 67 28.08 12.1 12 87.68 128.1 28.047 5.8225 55.8186 4.87 6.18
STD DEV4.7 11.28 15.7 0.07 7.185 14.09 5.78 3.08 2.5 17.39 34.93 39.346 12.204 27.837 0.97 8.82
Sl.No Waist Hip W/H rat Ht Wt BMI GOITRE USG LO RO FBS PPBS F.Ins TSH TESTO FBS mmol HOMA‐IR BIO‐TEST
1 95 117 0.81 155 83 34.55 1 B/L PCO 13 14 89 114 23.68 11.2 89.8 4.94 5.20 31.43
2 96 112 0.86 155 76 31.63 1 B/L PCO 11 12 80 89 23.6 10.3 40.1 4.44 4.66 14.035
3 82 109 0.75 161 70 27.01 1 B/L PCO 14 9 107 129 11.1 8.29 71.9 5.94 2.93 25.165
4 85 101 0.84 160 65 25.39 1 B/L PCO 10 13 72 147 30 8.6 72 4.00 5.33 25.2
5 86 106 0.81 148 70 31.96 0 B/L PCO 11 13 96 172 52 25.4 69.4 5.33 12.33 24.29
6 81 94 0.86 140 57 29.08 1 B/L PCO 15 10 72 138 30.4 5.5 77.5 4.00 5.40 27.125
7 78 93 0.84 150 54 24.00 0 B/L PCO 15 16 80 118 26.8 7.8 65.9 4.44 5.29 23.065
8 79 101 0.78 152 64 27.70 0 B/L PCO 11 11 84 145 20 6.6 45.6 4.67 4.15 7.7
9 105 123 0.85 159 95 37.58 0 B/L PCO 16 15 81 126 35 6.9 67.9 4.50 7.00 23.765
10 82 96 0.85 148 57 26.02 0 B/L PCO 15 13 72 90 24 28.5 90 4.00 4.27 31.5
11 90 112 0.80 153 58 24.78 0 B/L PCO 14 14 80 88 16 100 76.8 4.44 3.16 26.88
12 94 132 0.71 152 76 32.89 0 B/L PCO 13 10 96 124 20 6.2 61 5.33 4.74 21.35
13 76 90 0.84 144 60 28.94 0 B/L PCO 22 19 83 105 13 6.9 71 4.61 2.66 24.85
14 98 139 0.71 153 98 41.86 0 U/L PCO 13 9 97 130 74.7 5.5 94.3 5.39 17.89 33.005
15 96 112 0.86 155 76 31.63 1 B/L PCO 11 12 80 89 23.6 10.3 40.1 4.44 4.66 14.035
16 100 116 0.86 166 100 36.29 0 B/L PCO 11 9 72 112 12 5.11 88 4.00 2.13 30.8
MEAN 88.938 109.6 0.82 153.2 72.44 30.71 13.4 12 84 119.8 27.24 15.82 70.08125 4.66 5.74 24.01219
STD DEV 8.642 13.48 0.05 6.327 14.56 4.90 2.85 2.7 10 23.44 15.65 22.72 16.40024 0.57 3.86 6.767065
Sl.No WAIST HIP W/H HT(CM)WT(Kg BMI GOITRUGS  OV.VOL (LOV.VOL.(R FBS mg% PPBS mg% F.IN(mIU/LTSH(µIU/L)TESTO(ng) FBS(mmol/HOMA‐IR
1 86 107 0.80 140 62 31.63 0 B/L PCO 11 10 87 129 13.6 1.97 91.6 4.83 2.92
2 73 90 0.81 150 55 24.44 0 B/L PCO 12 10 56 128 12.6 4.33 26.2 3.11 1.74
3 72 92 0.78 156 55 22.60 1 B/L PCO 9 9 105 126 6.69 1.3 33 5.83 1.73
4 95 117 0.81 155 63 26.22 1 B/L PCO 9 10 62 74 16 3.1 40 3.44 2.45
5 86 115 0.75 162 76 28.96 1 B/L PCO 10 8 96 111 16.6 2.49 43.03 5.33 3.93
6 82 98 0.84 154 50 21.08 0 B/L PCO 12 14 80 115 4.5 1.23 96.5 4.44 0.89
7 85 103 0.83 170 75 25.95 0 B/L PCO 8 9 96 112 11.4 2.45 30 5.33 2.70
8 108 116 0.93 164 81 30.12 0 B/L PCO 9 11 115 175 29.73 2.03 141.7 6.39 8.44
9 92 107 0.86 155 100 41.62 1 B/L PCO 10 11 100 112 6.01 4.1 10.4 5.56 1.48
10 84 92 0.91 149 59 26.58 0 B/L PCO 9 10 84 124 16 1 84.8 4.67 3.32
11 70 84 0.83 162 48 18.29 0 B/L PCO 12 14 76 104 10 3 42 4.22 1.88
12 75 83 0.90 156 39 16.03 0 B/L PCO 10 12 86 104 7.4 1 22.8 4.78 1.57
13 80 98 0.82 159 55 21.76 0 B/L PCO 8 11 96 117 14.9 4.8 44.5 5.33 3.53
14 92 114 0.81 160 76 29.69 0 B/L PCO 12 13 90 114 247 1.13 49.5 5.00 54.89
15 94 99 0.95 170 73 25.26 0 B/L PCO 10 11 100 116 22 0.46 76.8 5.56 5.43
16 85 91 0.93 155 65 27.06 0 B/L PCO 10 11 72 104 6.1 1.3 17 4.00 1.08
17 76 89 0.85 148 53 24.20 0 B/L PCO 10 11 97 119 6.9 2.4 48.3 5.39 1.65
18 72 100 0.72 162 70 26.67 0 B/L PCO 12 14 79 108 10.5 0.46 13 4.39 2.05
19 77 98 0.79 150 56 24.89 0 U/L PCO 11 10 72 104 9.26 4.2 56.3 4.00 1.65
20 89 109 0.82 162 64 24.39 0 B/L PCO 12 15 168 318 31.4 2.32 26 9.33 13.03
21 78 88 0.89 150 50 22.22 0 B/L PCO 30 16 68 112 18.7 1.34 67.7 3.78 3.14
22 101 116 0.87 156 78 32.05 0 B/L PCO 11 11 79 114 10.5 1.95 43.1 4.39 2.05
23 80 102 0.78 148 62 28.31 0 B/L PCO 11 17 53 98 10 1.27 38.9 2.94 1.31
24 110 122 0.90 155 85 35.38 0 U/L PCO 10 6 74 152 7.6 2.12 67.9 4.11 1.39
25 111 129 0.86 153 96 41.01 0 B/L PCO 10 9 78 133 13 3.5 41 4.33 2.50
26 94 105 0.90 150 64 28.44 0 U/L PCO 11 9 66 144 28 3.5 10.9 3.67 4.56
27 84 91 0.92 156 55 22.60 0 U/L PCO 11 cyst 86 115 11.8 1.7 51.7 4.78 2.51
28 115 125 0.92 150 90 40.00 1 B/L PCO 9 12 69 112 16.8 4.88 59.9 3.83 2.86
29 97 113 0.86 150 65 28.89 0 B/L PCO 11 11 92 163 24 1.9 90 5.11 5.45
30 100 103 0.97 161 75 28.93 0 B/L PCO 12 13 92 133 36 3.4 98.8 5.11 8.18
31 71 90 0.79 161 57 21.99 0 B/L PCO 10 11 70 146 28 2.72 84.1 3.89 4.84
32 88 95 0.93 150 50 22.22 0 B/L PCO 12 9 132 178 30 2.36 88.1 7.33 9.78
33 88 98 0.90 140 56 28.57 1 U/L PCO 10 9 88 120 22 2.55 96 4.89 4.78
34 91 113 0.81 160 80 31.25 1 B/L PCO 10 10 156 178 11.34 1.31 60 8.67 4.37
35 100 118 0.85 142 75 37.20 0 B/L PCO 12 11 91 120 18.9 3.17 56 5.06 4.25
36 104 117 0.89 163 85 31.99 0 U/L PCO 12 not visible 82 122 26.8 1.85 80.6 4.56 5.43
37 94 108 0.87 148 58 26.48 0 B/L PCO 12 14 105 160 24 4.46 98 5.83 6.22
38 70 91 0.77 145 51 24.26 1 U/L PCO 10 8 126 140 21 3.49 51.4 7.00 6.53
39 102 146 0.70 148 85 38.81 0 B/L PCO 11 12 70 114 18 2.2 21 3.89 3.11
40 99 135 0.73 161 70 27.01 0 B/L PCO 10 10 91 143 25 3.73 41.8 5.06 5.62
41 90 130 0.69 155 59 24.56 0 B/L PCO 11 13 146 254 20 1 62.5 8.11 7.21
42 97 120 0.81 164 52 19.33 0 B/L PCO 13 19 78 102 34 1.1 22 4.33 6.55
43 85 100 0.85 168 68 24.09 0 B/L PCO 11 13 96 126 10.9 4 98.1 5.33 2.58
44 108 145 0.74 140 69 35.20 0 U/L PCO 10 8 91 121 13.24 1.2 29 5.06 2.97
45 66 88 0.75 143 47 22.98 0 B/L PCO 9 14 74 146 7.7 2.7 36.3 4.11 1.41
46 107 147 0.73 162 79 30.10 0 B/L PCO 12 9 87 123 31.6 4 31.9 4.83 6.79
47 93 123 0.76 154 76 32.05 1 B/L PCO 12 10 96 112 8.01 1.17 29 5.33 1.90
48 88 121 0.73 162 67 25.53 0 B/L PCO 12 11 86 115 33.8 4 55.7 4.78 7.18
49 84 92 0.91 149 59 26.58 0 B/L PCO 13 10 84 124 16 1 84.8 4.67 3.32
50 70 84 0.83 162 48 18.29 0 B/L PCO 12 14 76 104 10 3 42 4.22 1.88
51 75 83 0.90 156 39 16.03 0 B/L PCO 10 12 86 104 7.4 1 22.8 4.78 1.57
52 80 98 0.82 159 55 21.76 0 B/L PCO 15 10 96 117 14.9 4.8 44.5 5.33 3.53
53 92 114 0.81 160 76 29.69 0 B/L PCO 12 13 90 114 247 1.13 49.5 5.00 54.89
54 78 98 0.80 154 61 25.72 1 B/L PCO 13 13 94 122 17 4.8 38 5.22 3.95
55 94 99 0.95 170 73 25.26 0 B/L PCO 16 11 100 116 22 0.46 76 5.56 5.43
56 85 91 0.93 155 65 27.06 0 B/L PCO 15 11 72 104 6.1 1.3 17 4.00 1.08
57 78 98 0.80 154 61 25.72 1 B/L PCO 13 13 94 122 17 4.8 38.9 5.22 3.95
Mean 88.07 105.9 0.84 155.3 65.19 27.10 11.4035 11.80952 90.01754 128.7193 24.85404 2.454912 52.95316 5.00 5.64
Std Dev 11.91 16.07 0.07 7.453 13.39 5.70 2.95498 2.442073 21.62559 36.52673 43.17048 1.314178 28.0638 1.20 9.70
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TABLE: 1 
Shows the mean of all Physical & Biochemical parameters obtained for all 
participants.  
TOTAL PARTICIPANTS IN THE STUDY= 73 
 
PARAMETERS MEAN & STD- 
DEV FOR ALL 
PARTICIPANTS 
Reference interval 
AGE 24.79(±4.64)  
BMI 28.08(±5.78) 18.5-24.9 
WAIST/HIP RATIO 0.83(±0.07) <0.85 
FBS(mg/dL) 89.15(±19.75) 70-110 mg/dL 
2 HRS POST GLUCOSE 
(mg/dL) 
126.28(±34.65) <140 mg/dL 
FASTING 
INSULIN(mU/L) 
28.04(±39.34) 2.6-37.6 mU/L 
HOMA-IR 6.28(±8.8) <2.5 
TSH(mU/L) 5.82(±12.2) 0.3-5.0 mU/L 
 
 
TOTAL 
TESTOSTERONE(ng/dL)
55.8(±27.8) 14-76 ng/dL 
  
 
Table 1 shows the comparison of mean of age, BMI, W/H ratio, FBS, 2 hrs post 
glucose, Fasting Insulin, HOMA_IR, TSH, Total Testosterone between the study 
population and the expected reference interval. 
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TABLE: 4 
AGE DISTRIBUTION IN PCOS (73 PARTICIPANTS) 
AGE NO.OF. 
INDIVIDUALS 
PERCENTAGE 
<19 yrs(Adolescence) 8 10.9% 
≥20 65 89.04% 
 
   
  
            
Fig:3 - Shows the distribution of age in 73 PCOS women. There were 8 girls in 
adolescent age (<19), and 65 women belonging to age ≥20 yrs. 
 
                                                                      
  
<19
11%
>/=20
89%
AGE DISTRIBUTION
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TABLE: 5 
BODY MASS INDEX (BMI) FOR 73 PARTICIPANTS 
 
BODY MASS INDEX 
(BMI) 
NO. OF. 
INDIVIDUALS PERCENTAGE
UNDER WEIGHT 
<18.4 
4 5% 
NORMAL 
18.5-24.9 
19 26% 
OVERWEIGHT 
25-29.9 
27 37% 
OBESE 
≥30 
23 32% 
 
 
 
 
                    
 
Fig:4 - Shows the BMI distribution among the study population. 5% of women (4) 
were under weight, 26% (19) were normal, 37% (21) were overweight, 32%(23) were 
obese. 
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                                                    TABLE: 6 
                         
       DISTRIBUTION OF WAIST HIP RATIO FOR ALL PARTICIPANTS (73) 
W/H RATIO NO.OF 
INDIVIDUAL 
PERCENTAGE 
<0.8 23 32% 
 
>0.8 
50 68% 
 
 
 
              
 
Fig:5 - Shows the distribution of Waist / Hip ratio for all participants. 32% of them 
were having W/H ratio less than 0.8 and 68% of them had W/H ratio more than 0.8. 
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TABLE : 7 
THYROID FUNCTION STATUS IN ALL 73 PARTICIPANTS 
ASSOCIATION OF 
HYPOTYROIDISM 
NO.OF. 
INDIVIDUALS
PERCENTAGE 
 
HYPOTHYROID PCOS 
( >5µU/mL) 
 
16 
 
21.91% 
 
EUTHYROID PCOS 
(<5µU/mL) 
 
57 
 
78.08% 
 
 
 
                   
 
Fig:6 - Shows the prevalence of Hypothyroidism in the study population. ~22% 
(21.9%) of PCOS women (16) were found to have Hypothyroidism. 
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TABLE: 11 
GLUCOSE STATUS OF 
73 PCOS WOMEN 
FASTING 
GLUCOSE(mg/dL) 
( no. of individuals) 
2 HRS POST 
GLUCOSE(mg/dL) 
(no. of individuals) 
Normoglycemic 67 (<110 mg/dL) 58 
Impaired Fasting Glucose 
(110-126 mg/dL) 
2 - 
Impaired Glucose Tolerence 
(140-200 mg/dL) 
- 13 
Diabetes Mellitus 4 (>126 mg/dL) 2 (>200 mg/dL) 
 
 
TABLE: 12 
TOTAL PARTICIPANTS 73 
EUGLYCEMIA (no) 59 
IMPAIRED (no) 13 
DIABETES MELLITUS (no) 1 
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TABLE: 13 
DISTRIBUTION OF TESTOSTERONE LEVELS IN ALL 73 PARTICIPANTS 
 
SERUM TESTOSTERONE 
(ng/dL) 
NO.OF. 
INDIVIDUALS 
PERCENTAGE 
<76ng/dL 54 74% 
>76ng/Dl 19 26% 
 
 
Fig:12 - Shows the percentage of patients within the reference range of testosterone 
(<76 ng/dL). 26%had hyperandrogenism, 74% of them had normal level of 
testosterone.  
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TABLE: 14 
Group1: Euthyroid PCOS. 
Group2: Hypothyroid PCOS  
 
Fig:13      
COMPARISON OF BMI BETWEEN  
TWO GROUPS OF PCOS WOMEN 
 
                 
 
This table shows the mean BMI between the two groups of PCOS women.  
 
Mean BMI 
PCOS With Normal TSH 
27.10 
Mean BMI 
PCOS With Elevated TSH 
(Hypothyroidism) 
30.71 
P Value 0.026** 
 
STATISTICALLY SIGNIFICANT** 
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TABLE : 15 
COMPARISON OF WAIST HIP RATIO BETWEEN THE TWO GROUPS 
 Mean W/H Ratio For Euthyroid 
PCOS 
0.84 
Statistically Not 
Significant 
Mean W/H Ratio For Hypothyroid 
PCOS 
0.82 
P Value 0.28 
 
This Table shows the comparison of mean Waist/Hip ratio between the two groups of 
PCOS women. 
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TABLE: 17 
This Table shows the comparison of mean Fasting Insulin between the two groups of 
PCOS women.                                 
 FASTING 
INSULIN 
 
 
 
 
Not Statistically  
Significant 
EUTHYROID- PCOS 24.85 
HYPOTHYROID- PCOS 27.24 
P-VALUE 0.83 
 
STATISTICALLY SIGNIFICANT P VALUE <0.05 
                                                     
TABLE: 18 
COMAPRISON OF MEAN HOMA –IR BETWEEN EUTHYROID & 
HYPOTHYROID PCOS WOMEN 
                      
 MEAN HOMA-IR  
 
 
Not Statistically  
Significant 
EUTHYROID-PCOS 5.64±9.79 
HYPOTHYROID- PCOS 5.74±3.99 
P VALUE 0.96 
 
STATISTICALLY SIGNIFICANT P VALUE= <0.05 
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TABLE : 19 
 
 MEAN 
TESTOSTERONE 
 
 
 
 
Statistically Significant 
And Weak Positive 
Correlation 
EUTHYROID- PCOS 52.95 
HYPOTHYROID-PCOS 70.08 
P VALUE (<0.05) 0.023** 
Correlation of Total 
Testosterone With 
Hypothyroidism In 
PCOS 
0.14 
 
STATISTICALLY SIGNIFICANT P VALUE= <0.05** 
This Table shows the comparison of mean Total Testosterone between the two 
groups. 
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TABLE : 20 
NUMBER OF 
PARTICIPANTS 
73  
 
 
POSITIVE AND WEAK 
CORRELATION. 
CORRELATION OF 
TESTOSTERONE WITH 
W/H RATIO IN PCOS+ 
HYPO T PATIENTS 
0.38 
 
 
SHOWS CORRELATION BETWEEN TESTOSTERONE & WAIST HIP 
RATIO IN PCOS PATIENTS WITH HYPOTHYROIDISM 
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TABLE : 21 
Parameters Euthyroid-Pcos 
Hypothyroid-
Pcos 
Pearson Coefficient 
Correlation 
Significant P 
Value(<0.05) 
BMI 27.10+/- 5.75 30.71 0.026** 
WAIST / HIP 
RATIO 
0.84+/- 0.05 0.82+/- 0.07 0.28 
OVARY 
VOLUME 
11.39+/- 2.6 12.98+/- 2.8 0.03** 
FASTING 
BLOOD SUGAR 
90.01+/-21.81 83.81+/-10.5 0.27 
2 HRS POST 
GLUCOSE 
128.7+/- 
36.85 
119.75+/- 24.2 0.36 
FASTING 
INSULIN 
24.85+/-43.45 27.24+/- 16.16 0.83 
HOMA-IR 5.64+/- 9.79 5.74+/-3.99 0.96 
TESTOSTERONE 52.95+/-28.06 70.08+/- 16.93 0.023** 
 
** SIGNIFICANT P VALUE 
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Fig. 16 shows different variable mean comparison between Euthyroid & hypothyroid 
PCOS women. 
In our study population the mean age was 24.79 (±4.64), 88% of 73 PCOS patients 
had 2/3 criteria (menstrual irregularity+ USG finding) while 76.6% had clinical 
features of hyperandrogenism & USG –PCO finding, Biochemical features of 
hyperandrogenism & USG-PCO were observed in 26% & 60% women presented with 
all 3 criteria (Rotterdam), Table: 2. 
 Table:3 shows the percentage distribution of different presenting complaints 88% 
women presented with menstrual disorders, 74% came for infertility, 56% came with 
acne / hirsutism, 64% came with rapid weight gain. Table: 4 gives the prevalence of 
PCOS among adolescence (teenage) and adults(≥ 20yrs). In our study we had 8 girls 
aged ≤19yrs, 65 women ≥ 20yrs. In our study, most of the participants were obese. 
Table: 5 show the prevalence percentage of obesity based on BMI was 5% under 
0
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weight, 26% were normal, 37% were in overweight category & 32% obese (clinical & 
morbid). Table: 6 gives the Waist/Hip ratio distribution for the entire study group. 
32% (23) had their W/H ratio < 0.8 & 68% (50) had >0.8. Table:7, Shows the thyroid 
function status for all the participants based on TSH with cut-off level of about 
5µU/mL. Table:7 gives the serum TSH distribution in various age group. Age 
between 15 to 20 showed the mean TSH of about 2.93, 20 to 25yrs age group showed 
the mean of 8.22, 25-30 yrs groups showed 4.52 as their mean TSH, and 30-35 yrs 
group women showed 2.85 as their mean. The trend of TSH shows that the peak is in 
between 20s to 30s. Table:9 Gives the distribution of Fasting blood sugar in the study 
population. 67 of the participants had normoglycemia (70-110 mg/dL), 4 of them had 
FBS more than 126mg/dL, 2 of them had impaired fasting glucose. Table: 10, shows 
the distribution of 2 hrs post glucose level in all the 73 participants. 59 people showed 
normoglycemia, 13 were in impaired glucose Tolerance, and one of them was frank 
diabetic. Table: 11, gives the overall distribution of FBS and 2hrs PP for all the 
participants and the following table (12) gives the full statistics. Table: 13, shows the 
serum testosterone level among the PCOS women. Table: 20, showed the difference 
between the mean of BMI, Waist/Hip ratio, FBS, 2 hrs PP, Fasting Insulin, 
Testosterone, Ovarian volume, HOMA-IR between the two groups. BMI, 
Testosterone, Ovarian volume, showed statistical significance between them. There 
was no statistical difference in Waist/Hip ratio, Fasting Insulin, HOMA-IR between 
the two groups.   
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DISCUSSION 
As the incidence of infertility and its morbidity are increasing in the recent 
days, the root cause should be identified and treated accordingly. The leading cause 
for female infertility is menstrual irregularities apart from anatomical and genetic 
defects. Major contributing factors for this irregular menstruation are from local 
(ovarian) cause like Polycystic ovarian Syndrome and /or the systemic cause like 
Hypothyroidism, Hyperprolactinemia, Hyperinsulinemia. All the above said factors 
pose individual risk for anovulation. Often they present in combination. PCOS and 
hypothyroidism are the most common endocrine disorders found in young 
reproductive age group women. A common finding in gynaecology outpatient 
department is that while treating individuals for PCOS for a period of few months, in 
some patient menstruation and ovulation is restored while it remains uncorrected in 
some individuals. On further evaluation of these non-responding patients for the other 
causes of infertility / menstrual disorder they were found to have co-existing 
Hypothyroidism which was mostly undiagnosed and /or untreated. These individuals 
were found to be mostly in subclinical status and some in overt hypothyroid state. 
Screening studies helps to assess the prevalence of hypothyroidism and gives an 
insight about the epidemiology of this disorder in the population. However studies 
comparing thyroid status in PCOS women is very minimal in all regions of India. 
With this background we have undertaken this study with the aim to estimate the 
thyroid function status in newly diagnosed PCOS patients  
     A cross sectional study was conducted among 73 newly diagnosed PCOS 
women attending the Gynaecology & Endocrinology outpatient department for 
menstrual irregularity and infertility. They were diagnosed based on revised 
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Rotterdam criteria, 2003.  With serum TSH level of 5µU/L as the cut-off point to 
diagnose hypothyroidism  we have identified the prevalence of  hypothyroidism  
among 73 newly diagnosed PCOS women to be about 22% (no:16). In a case control 
study conducted by Maryam et al. a significant prevalence of auto immune thyroiditis 
and goiter in PCOS [166] was reported. Sridhar et al reported a prevalence of 1.04% 
(2/13) of polycystic ovaries among hypothyroid patients. In our study, 22% of our 
patients had hypothyroidism. This shows that there is a correlation between thyroid 
dysfunction and PCOS which is also supported by the findings of Maryam et al & 
Sridhar et al.[175]  A similar finding of hypothyroidism among PCOS women was 
observed by Onno E Janssen et al study (20.6%)[167]. 
PREVALENCE OF HYPOTHYROIDISM & SUBCLINICAL 
HYPOTHYROIDISM IN VARIOUS CONDITIONS[168,169] 
TABLE:VI 
 
GENERAL 
POPULATION INFERTILITY 
PEER 
GROUP 
PCOS 
STUDY [163] 
THIS STUDY 
HYPO-
THYROIDISM 
10-11% 
2-4% (20-40 yrs 
women) 
23.9% 2.5% 22% 
(21.91%) 
 
The age distribution of TSH table and trend of TSH in PCOS shows that serum TSH 
level was at maximum between 20-30yrs. This peaking may be because the 
requirement of thyroxin is high in this age for all organs including reproductive 
system, which can be considered as an extension of physiological hypothyroidism. If 
physiological demand for thyroxin is not quenched adequately it might be a reason for 
developing subfertility later and ultimately leading to infertility.   
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Table: 1 shows the comparison of mean of all parameters for the study population 
against the reference interval. From this it is understood that BMI, Fasting Insulin, 
HOMA-IR, TSH & Testosterone were higher among PCOS patients than the 
reference values. This infers that obesity, hyperinsulinemia, hypothyroidism, 
hyperandrogenism are all the major contributing factors for PCOS. 
Based on TSH cut-off value of 5µU/mL, the entire study population was divided into 
2 groups. Group1: PCOS with Euthyroid & Group2: PCOS with Hypothyroid. 
Euthyroid PCOS women comprised 78% while hypothyroid PCOS women 22%.  
Testosterone was significantly elevated in hypothyroid patients when compared with 
the euthyroid group. (Table:19) Mean testosterone of group 1 was 52.95(±28.06) 
while in group 2 it was 70.08(±16.93) and the difference was statistically significant   
(P value 0.023). On comparing the testosterone values with that of TSH for the two 
groups we found observed a positive but weak correlation for hypothyroid group  
(r = 0.14).  There was no correlation between Testosterone and TSH for the euthyroid 
group. This infers that as TSH rises Testosterone also increases and indicates that 
Hypothyroidism is a contributing factor for hyperandrogenism and its sequale  
(polycystic ovarian syndrome). This also infers that the existing hyperandrogen status 
is worsened by the co existence of hypothyroidism. This may be the cause for 
persistence of complaints like menstrual disorders, infertility, USG – finding of cysts 
in some patients having treated for PCOS. This reinforces the importance of 
evaluating serum TSH in a patient diagnosed as PCOS.  
Table 14: Gives the comparison of mean BMI between Group 1=27.1(±5.75) 
Group2 =30.71(±5.06) with statistically significant P value of 0.026. As thyroid 
hormones are essential for lipid and protein metabolism, in hypothyroidism the 
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function is slowed down (hypometabolism) leading to fat and extracellular matrix 
deposition leading to obesity.  
Table: 15, Shows the comparison of mean Waist / Hip ratio between 
Group1=0.84(±0.07) & Group2 =0.82(± 0.05). We have not observed any significant 
variation between the groups. This shows that the distribution of fat is not different in 
2 groups as all of them are having PCOS. The overall mean W/H ratio was 0.83 
slightly in the upper expected limit (0.85) indicating that PCOS women are basically 
towards developing truncal obesity. 
In table:16, comparison of mean FBS & 2hrs Post glucose between the 2 groups were 
shown and was not significant. Table:17 Comparison of fasting Insulin between 
Group1=24.85(±43.45) and Group 2=27.24(±16.16) showed P value 0.83 and mean 
HOMA-IR of Group1=5.64(±9.79) and Group 2=5.74(±3.99) with P value 0.96. This 
implies that there is no difference in Blood sugar and Insulin levels between those 
who have euthyroid and hypothyroid status. This may be because the serum TSH for 
most of the patients diagnosed as hypothyroid  were possibly in subclinical state and 
the metabolism might not have been significantly affected. But the mean HOMA-IR 
of the study group (6.28±8.8) when compared with the reference range (<2.5) is very 
much high indicating that the study population have insulin resistance universally [170]. 
From our study, we have found that the 59 patients had normoglycemia, 13 had 
impaired glucose level and one patient had both FBS and 2hrs PP in diabetic range.  
The mean ovarian volume between the 2 groups showed a significant 
difference. Group 1had a mean value of 11.39cc (±2.6) & Group2 had a mean value 
of 12.98cc (±2.8) with P value=0.03. PCOS women with hypothyroidism had higher 
ovarian volume than PCOS with euthyroid state. In hypothyroidism, there is collagen/ 
  100
cellular matrix deposition in most parts of the body including the ovaries increasing 
the ovarian volume and impairs their function. Also the cyst number is expected to be 
higher with thyroid dysfunction further contributing to increase in ovarian 
volume[171,172]. This again emphasises the importance of screening for hypothyroidism 
in newly diagnosed PCOS women and as per the recommendation of American 
Thyroid Association 2012, serum TSH alone can be used to rule out thyroid disorders. 
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SUMMARY 
A cross sectional study was conducted in 73 newly diagnosed Polycystic 
Ovarian Syndrome patients. Among 73 participants, 16 were diagnosed to have 
hypothyroidism based on serum TSH (Thyroid Stimulating hormone) level with the 
cut-off value of 5µU/mL. They were divided into 2 groups. 
Group: 1 PCOS women with euthyroidism. 
Group: 2 PCOS women with hypothyroidism. 
From our study, we found that: 
1) Mean BMI, Waist / Hip ratio, Fasting Insulin, HOMA-IR, Testosterone among 
PCOS patients were found to be higher than the recommended reference 
range. 
2) The prevalence of hypothyroidism in PCOS patients was (22%), which is 
higher than the prevalence of hypothyroidism in general reproductive age 
women (2-4%). Thus, prevalence studies helps to bring many submerged / 
occult disorders to light there by aiding in correct diagnosis and proper 
treatment.     
3) Our study followed the American Thyroid guidelines recommendation of 
using serum TSH alone instead of the entire thyroid profile for screening 
hypothyroidism in adults outpatient department which may be cost effective 
and economical for the patients and the health care providers. 
4) Comparison of mean Testosterone between euthyroid and hypothyroid patients 
shows that hypothyroidism poses an additional contributing factor in 
developing features of hyperandrogenism, subfertility, infertility and even 
ovarian failure. 
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CONCLUSION 
Polycystic Ovarian Syndrome, an ill defined complex disorder and needs a 
keen attention while treating. As ethnicity plays a vital role in this disorder, the 
characteristics of this disorder in different population should be known. There exists a 
cycle in the pathogenesis of PCOS from hypothalamus to ovary and vise-versa. The 
ultimate finding is hyperandrogenism. Systemic disorders like Hypothyroidism, 
Hyperprolactinemia, Hyperinsuliemia also contributes to hyperandrogenism by 
reducing the hepatic SHBG production. All these factors lead to hormonal imbalance 
affecting ovarian homeostasis resulting in anovulation. The final outcome may be 
single or multiple,from simple acne to complicated infertility. Very often these PCOS 
women were found to have hypothyroidism remaining submerged / undiagnosed 
which augments the existing hyperandrogenism. Timely and appropriate 
investigations can halt this cyclical event and its progression by early diagnosis and 
treatment. 
From this study, it is concluded that : 
Hypothyroidism is definitely an important contributing factor for 
hyperandrogenism, hence screening for hypothyroidism along with reproductive 
hormone profile should be evaluated in PCOS / infertile women for early diagnosis 
and management.    
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LIMITATIONS OF THE STUDY 
1. This is a cross sectional and observational study conducted on a small group 
comprising of 73 subjects diagnosed as PCOS, who were further grouped based 
on their thyroid function status into euthyroid and hypothyroid. All data were 
compared between the two groups only. Hence some of the parameters did not 
show statistical significance as PCOS was a common factor for the two groups. A 
case- control study would have provided more information on the hormonal status 
of healthy women in reproductive age group (controls) and the comparison with 
PCOS individuals( cases) would have provided a better statistical significance. 
 
2. The hyperandrogenic status of the patients in this study was biochemically 
confirmed by measuring only Total testosterone rather than both total and free 
hormone due to cost limitations. Although all patients in this study had clinical 
features of hyperandrogensm, we found that 74% of the patients had normal 
testosterone, and only 26% of the patients were biochemically hyperandrogenic 
(as per the reference range of the kit used). Perhaps the free testosterone levels  
(which was not measured) of these patients was possibly higher contributing to the 
clinical features of hyperandrogenism. 
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SCOPE FOR FURTHER STUDY 
1. The reference range of various hormones for our ethnic population in different 
age group can be worked out in future studies. 
2. As obesity is a very common finding in PCOS and Hypothyroidism, 
association of certain serum adipokines with PCOS and infertility can be 
considered for further studies. 
3. A case-control study with more number of subjects can be done which will be 
useful for statistical analysis and provide more information on the mechanism 
of interplay of the various hormones. 
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PROFORMA 
 
NAME  :                  DATE: 
 
AGE  :                                  SEX  :                    PROJECT SERIAL NO: 
 
IP/OP  NO :                  CASE/CONTROL: 
 
ADDRESS : 
 
CONTACT NO: 
 
SAMPLE COLLECTION CENTRE  : 
 
MAIN COMPLAINTS    :  MENSTRUAL IRREGULARITY    OLIGO/AMENNORRHOEA  INFERTILITY  
          WEIGHT GAIN      OTHERS  LMP 
          DURATION _______________   
 
ASSOCIATED COMPLAINTS  :  ACNE  HIRSUITISM     HYPERTRICHOSIS 
     RECURRENT PREGNANCY LOSS  GALACTORRHOEA  OTHERS 
 
MENSTRUAL HISTORY    :  MENARCHY AGE CYCLE : REGULAR/IRREGULAR DURATION_____ 
          ASSOCIATED WITH ABDOMINAL PAIN 
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                                                             ABORTION   NO      GESTATIONAL AGE 
 
FAMILY HISTORY    :  MOTHER CYCLE:   SISTER:  AUNTY: 
 
TREATMENT HISTORY    :  OC.PILLS  THYROXINE CORTICOSTEROIDS ANTIEPILEPTICS 
          AMIADARONE    OTHERS  DURATIION_________________ 
 
CLINICAL EXAMINATION  :  HEIGHT: __________   WEIGHT: __________     BMI: __________ 
                                                                     Waist:                    Hip: 
 
 

 
          CLINICAL EXAMINATION OF THE :  NECK:     
                    BREAST: 
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  FASTING GLUCOSE  :         
               2HRS POST GLUCOSE     : 
  FASTING INSULIN  : 
  TSH                                     :                       
               TESTOSTERONE     : 
  ULTRASOUND   PELVIS & OVARIES:            
 
 
   





